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SUMMARY
The metabolism of two aromatic nitro chemotherapeutic agents 
has been investigated. One, 2-isopropylaminomethyl-6-methyl-7-nitro-
1,2 ,3,4-tetrahydroquinoline (methamniquine) is a potent schistosomicide; 
the other 5 *7“dinitroindazole possesses tuberculostatic activity.
Methamniquine is oxidised in vervet and rhesus monkeys, dogs, 
rabbits, hamsters, rats and mice, to its 6-hydroxymethyl analogue 
(oxamniquine), a metabolite which shows a greater degree of schistosomicidal 
activity than the parent drug. Further oxidation at the 6-position occurs 
in all species to yield a carboxylic acid which is the major urinary 
metabolite in all species. When oxamniquine is administered to the same 
species and to man this same acid is again found as the major metabolite. 
Oxidation of the alkylaminoalkyl sidechain also occurred to a variable 
extent in all species studied to give a second carboxylic acid with the 
exception of the rat which oxidised the sidechain to an alcohol which was 
excreted in the bile as a glucuronide. The reason for this species 
difference in metabolism has been investigated and a possible biochemical 
mechanism is proposed. Reduction of these compounds was apparently not a 
significant route of metabolism.
The urinary metabolites of dinitroindazole have been examined 
in mice and rats. The drug is extensively metabolised. Selective 
reduction of the 7-nitro group occurs in both species to give 5“ni'tro” 
7-aminoindazole as the major metabolite. Hydroxylation of the indazole 
ring also occurs to give 3~hydroxy-dinitroindazole, a minor metabolite 
in both species. A species difference is apparent in the further metabolism 
of 5«nitro-7-arainoindazole. In mice extensive N-glucuronidation is 
found, a synthesis not evident in the rat. In this species acetylation
occurs to yield 5'"nitro-7~acetamidoindazole* This metabolite is the 
probable precursor of two other metabolites in the rat. One of these 
has been positively identified as 3"hydroxy-5~nitro-7-acetamidoindazole. 
The other is suggested to be an N-hydroxylated derivative.
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The Relevance of Drug Metabolism Studies in Toxicity Testing
The phrenetic research endeavours of modern man cover every 
field of human activity, not least that of therapeutic medicine, an 
area in which great advances have been made. We are now in possession 
of a large number of drugs, both medicinal and chemotherapeutic 
agents, used in combatting disease states and the search for new and 
better drugs is a particularly active area of medical research. The 
flood of new drugs which have been introduced during the last thirty 
years and the experience gained by their use have made us conscious 
of the urgent need for more knowledge of drug safety if we are to. 
avoid further disasters such as the thalidomide tragedy of the early 
1960s. As a result a new species of research investigator is evolving - 
the drug toxicologist - whose duty is„to assess the potential toxicity 
of new drugs in man by careful consideration of data accumulated from 
experiments in well-chosen animal models. He is required to be a 
modern-day Proteus, a multidisciplinarian, a hybrid of biochemist, 
pharmacologist and pathologist. The problems facing the toxicologist 
attempting to predict drug safety in man are many and even after 
exhaustive animal studies have been undertaken predictions can never be 
infallible.
Whenever new drugs are given to man for the first time there 
will be an attendant risk. These risks can however be minimised 
through knowledge of a drug’s metabolism. The selection of suitable 
animal models for toxicity testing has all too frequently in the past 
been quite empirical and determined by such factors as convenience and 
availability rather than any sound rationale. The incorporation of 
comparative metabolism studies in drug evaluation programmes, including 
studies of absorption, distribution and excretion and a correct
interpretation of the results enables many aspects of the investigation 
of toxicity to be more rationally based and facilitates extrapolation 
of data from animals to man. Herein lies their true importance. For 
a detailed treatise on this subject the reader is referred to the 
report prepared for the Drug Research Board, National Academy of Sciences 
by its committee on problems of drug safety (1969),
Whilst metabolism studies are now expected to form one of the 
cornerstones in the -evaluation of a new drug, the acquisition of reliable 
data is often no mean task. There are a number of fundamental difficulties 
involved in the running of large numbers of properly controlled 
experiments in comparative toxicity. Dearborn (1967) lists over 40  
modifiers of the results of such studies under the principal headings of
(a) Internal environmental factors such as sex, age, weight, nutritional 
state, etc,; (b) External environmental factors such as temperature, 
humidity, season, time of day, etc,; and (c) Drug administration 
factors such as route, site and rate of administration, volume and 
frequency of dose, etc, A number of these factors apply to the metabolism 
studies to be described in this thesis and were largely beyond the 
writer's control as experiments were frequently designed for reasons other 
than comparative metabolism studies.
Before the results of these investigations are described a 
brief review of existing knowledge of the subject is given, so far as 
it affects a fuller understanding and interpretation of the experimental 
findings to be outlined later, covering general pathways of metabolism 
of foreign compounds with particular reference to nitro compounds ;- 
2.(a) Metabolism of Foreign Compounds
Man in his modern environment is continually exposed 
to a host of substances which may be ingested either accidentally
or intentionally. These include not only our drugs but food 
additives, pesticides, industrial chemicals and some natural 
products. Many of these substances have no part to play in the 
normal processes of intermediary metabolism nor have they any 
nutritional value, and for this reason they have been termed 
'foreign compounds'. Some of these foreign compounds are quite 
innocuous but a great number are toxic to both man and animals 
and complex enzyme systems have evolved in living organisms 
to deal with these potential hazards to life. The major route 
of entry to the body of foreign compounds is through the gastro­
intestinal tract from where they are absorbed and pass via the 
portal vein to the liver; it is thus not mere coincidence that 
the liver is found to be the principal site of metabolism of 
toxic substances. Other organs and tissues which are active in 
metabolising toxic substances are the kidneys, intestines, lungs 
and skin all of which are concerned with absorption or excretion, 
thus the body appears to have developed a first line of defence 
against foreign compounds at strategic sites where entry or exit 
to the body is facilitated.
The majority of chemicals regarded as foreign to the 
body, including a large number of drugs,are lipophilic substances 
which when absorbed are not readily excreted. The function of 
the defensive enzyme systems is to transform these foreign 
compounds, both toxic and non-toxic alike, into more water- 
soluble materials that can more easily be excreted. These 
metabolic transformations consist of two phases. The reactions 
of the first phase include a diverse variety of oxidations, 
reductions and hydrolyses designed to introduce or uncover
reactive groups such as OH, COOH, SH and NH , resulting in an 
increase in polarity of the molecule and providing a centre for 
the second phase reactions. A summary of the more important 
Phase I reactions is given in Table 1.
TABLE 1 .1 . ■ ;
Preconjugative Reactions and Subcellular Location
Chemical
reaction
Microsomal
drug-metabolizing
enzymes
Non-microsomal 
mammalian enzymes
Oxidation
(oxygenation)
Reduction
Hydrolysis
Aromatic 
hydroxylation 
Acyclic 
hydroxylation 
Alicyclic 
hydroxylation 
Epoxidation 
N-Oxidation 
S-Oxidation 
Desulphurat i on 
Dealkylation 
Deamination
Nitro reduction
Azo reduction 
Dehalogenation
Hydrolysis of 
esters
Alcohol oxidation 
(cytoplasm)
Aldehyde oxidation 
(cytoplasm)
Alicyclic aromatization 
(mitochondria)
Deamination 
(mitochondria and blood 
plasma)
Reduction of sulphoxides 
and N-oxides (cytoplasm) 
Reduction of disulphides
Hydrolysis of esters and 
amides (blood plasma) 
Hydrolytic ring scission 
Dehalogenation 
(cytoplasm)
The reactions of Phase II are biosyntheses and appear 
. to be of two distinct types. The one consists of conjugation 
with endogenous molecules such as glucuronic acid, sulphuric 
acid and the amino acids glycine and glutamine all of which 
result in a further increase in water-solubility and assist in 
excretion, the other involves the transfer of methyl and acetyl
groups from endogenous donors to foreign molecules containing 
phenolic, thiolic and amino groups, and does not necessarily 
increase aqueous solubility. The principal conjugations and 
the co-enzymes required are listed in Table 1,2.
TABLE 1.2
Conjugative Reactions and Co-enzymes Involved
Chemical
reaction
Functional
groups
conjugated
Co-enzyme
Glucuronide
formation
Hydroxyl, 
carboxyl, 
amino, thiol
Uridine diphosphate 
glucuronic acid
(u d p g a)
Sulphate
ester
formation
Hydroxyl,
amino
3 ’-Phosphoadenosirie- 
5,-phosphosulphate 
(PAPS)
Methylation Hydroxyl, 
amino, thiol
S-Adenosylmethionine
Acetylation Amino,
sulphojkmido,
hydrazino
Acetyl co-enzyme A
Peptide
formation
Carboxyl Acyl or aroyl 
co-enzymes A
Glutathione
conjugation
Epoxides; 
halogen, 
nitro and 
sulphonamido 
(displaced)
Unknown
Thiocyanate
formation
Cyanide Unknown
This subject has been well reviewed by several writers. 
The reader is referred to the monographs of Williams (1959) and 
Parke (1968a) and to review articles by Parke (1968b),Parke and 
Williams (1969), and the recent monumental reference work 
"Concepts in Biochemical Pharmacology" (Eds. Brodie and Gillette 
1971).
Localisation of Drug Metabolising Enzymes
The enzymes which catalyze these transformations are 
located chiefly in the hepatic cells of the liver and the most 
important class, that which metabolises compounds by a process 
of hydroxylation or oxygenation is more specifically found bound
to the endoplasmic reticulum, a membranous network of lipoprotein 
tubules which extends throughout the cytoplasm. Electron microscopy 
clearly demonstrates that the membranes of the endoplasmic reticulum 
are of two morphologic types, rough and smooth, distinguished by 
the presence or absence of bound ribosomes.
Homogenisation of tissues destroys the integrity of this 
network and the membranes are broken up into small vesicles for 
which Claude 11943) coined the term ’microsomes1. Centrifugation 
of liver tissue homogenates at 1 0 ,0 0 0 g for 20 minutes deposits 
cell nuclei, mitochondria and other cellular debris, the microsomes 
can then be sedimented from the 1 0 ,0 0 0 g supernate as a pellet by 
further centrifugation at 1 0 5 ,0 0 0 g for 1 hour. -
Smooth and rough microsomal membranes appear to differ 
in their levels of drug-metabolising enzyme activity. The highest 
levels of activity are generally found in the smooth membranes 
(Fouts 1961, Fouts et_ al^  1966), but there are some notable 
exceptions, for example the activity of UDP-glucuronyl transferase 
in rabbit liver towards certain substrates was found to be about 
twice as high in rough membranes as in smooth membranes (Gram et al 
1968).
Microsomal Hydroxylation
The characteristic biotransformation reaction catalysed 
by the microsomal enzymes is an oxidation or hydroxylation. These 
enzymes display remarkable non-specificity and a wide variety of 
substrates are oxidised by what appears to be a common mechanism. 
They show a requirement for both NADPH and molecular oxygen and 
are typical mixed-function oxidases (Mason 1957)* The mechanism 
by which drug oxidation is effected was until recently poorly 
understood as the enzyme system has several components ;,and has
been difficult to study on account of its extreme lability when 
solubilised.
Our current knowledge' owes much to the pioneering work 
of Omura et al_ (1962, 1964a, 1964b, 1965 and 1966) who described 
the microsomal hemoprotein - cytochrome P-4 5 0 ” and subsequently 
demonstrated that it functions as the terminal oxidase responsible 
for the activation of molecular oxygen and its incorporation into 
substrate molecules. They proposed an electron transfer system 
from NADPH to the terminal cytochrome involving a flavo-protein 
and a non-heme iron protein as intermediates. The flavo-protein 
is now considered to be NADPH-cytochrome c reductase, which was 
first observed by Horecker (l950) and later purified by Williams 
and Kamin (1962). -
According to the current view, drug oxidation occurs by 
the following sequence of events. The drug forms a complex with 
the oxidised form of P-45O which is then reduced either directly 
or indirectly through an unidentified carrier by NADPH-cytochrome 
c reductase. The reduced drug-P-450-complex then reacts with 
molecular oxygen .to form an 'active oxygen'-P-450“drug complex 
which then breaks down to give oxidised drug, oxidised P -4 5 0 and 
water.
Liver microsomal drug metabolising activity can be 
induced by a wide variety of agents such as hormones, drugs, 
insecticides and carcinogens. The induction of microsomal enzymes 
is important pharmacologically as it leads to increases in the 
rate of drug metabolism. Further discussion of this topic is 
inappropriate here and the reader is referred to the excellent 
review by Conney (1967) and to a review by Gelboin which has
appeared in two reference works (l971a, 1971b).
The rate of hepatic microsomal drug metabolism was 
thought by a number of investigators to be closely related to 
the amount of P-45O in microsomes (Orrenius and Ernster 1964,
Remmer et al 1968). It now appears likely that the rate-limiting 
step is reduction of the P-450 drug complex (Gillette and Gram 
1969, Gillette 1969, Davies et_ al_ 1969).
Nitro Compounds and the Metabolism of Nitro Groups
This thesis is concerned with the metabolism of two
chemotherapeutic hgents, one a schistosomicide,, the other a
tuberculostatic drug. They share a slight degree of structural 
similarity in that they both possess aromatic nitro groups. It 
is pertinent therefore to consider briefly some of the various 
types of nitro compounds which are known and the particular 
metabolism of the nitro group.
(i) Naturally Occurring Nitro Compounds
The first natural product recognised to possess a
nitro group was the antibiotic chloramphenicol (Rebstock
et al 1 949)« Since then a number ofother nitro aromatic
substances have been discovered including azoraycin 
(2-nitroimidazole) (Nakamura 1955) and aureothin (Maede 19^3), 
and also alkyl nitro compounds such as the glycosides hiptagen 
and miserotoxin which contain the respective residues, 
3-nitropropionic acid (Carter and McChesney 1949) and 
3~nitro-l-propanol (Stermitz) et_ al 1969)# For a more 
comprehensive coverage of this topic see Venulet and Van Etten
(1970)* Most of the naturally occurring nitro compounds
exhibit antibacterial or other antibiotic properties.
Although their biological role is uncertain it seems
(ii)
(iii)
most probable that their function in plants is a protective 
one, to guard against parasitic invasion by bacteria or fungi 
or ingestion by animals.
Synthetic Nitro Compounds
The nitro group is a recurring theme in drug design, 
particularly in the field of chemotherapeutic agents where 
nitro containing drugs in current use include the nitrofuran 
antibacterials, e.g. nitrofurazon (5-nitro-furfuraldehyde 
semicarbazone), nitrofurantoin (N-[5-nitro-2-furfurylidene3-
1-amino-hydantoin) and furazolidone (3-{jj-nitrofurfurylidene- 
amino]-2-oxazolidinone, the antiprotozoal metronidazole 
(l-[2-hydroxyethyl]-2-methyl-5-nitroimidazole) and the anti- - 
helmintic yomesan (N-[2-chloro-4“nitrophenyl]-5“Chlorosalicylamide). 
Other drugs include nitrazepam (1,2-dihydro-7-’nitro-2-oxo-5“ 
phenyl-3H-l,4~benzodiazepine) a hypnotic, and nicoumalone 
(3-[a-acetonyl-4~nitrobenzyl]-4“hydroxycoumarin) an anticoagulant. 
The nitro group is also a feature of a number of insecticides, 
e.g. parathion (0,O-diethyl O-p-nitrophenyl phosphorothionate) 
arid herbicides, e.g. DNOC (2,4-dinitro-orthocresol).
Reduction of Nitro Groups in vitro
The characteristic metabolic reaction of aromatic 
nitro groups is reduction to give the corresponding amines.
The chemical reduction of aromatic nitro groups to 
primary amines proceeds stepwise through nitroso and hydroxyl- 
amine intermediates and requires six equivalents of reducing 
agent (Fig. l).
2 [H] 
- H O
2 [H]
NO
2
NO HNOH
Fig. 1
There is satisfactory evidence that bioreduction follows a 
similar pathway. Channon et_ al_ (1944) isolated a hydroxyl- 
amine from rat urine after dosing with trinitrotoluene (TNT) 
and Bueding and Jolliffe (l94&) demonstrated reduction of the 
same compound in vitro by a flavoprotein and by xanthine 
oxidase. The end product with the former was believed to be 
nitrosodinitrotoluene and with the latter was hydroxylamino- 
dinitrotoluene. The rate of disappearance of TNT in liver 
incubations under anaerobic conditions was greater than the 
rate of formation of the corresponding amine. In contrast 
studies with nitrobenzoic acid (Gillette et al, .1968). and 
with nitrobiphenyl (Uehleke and Nestel, 1967) indicate that 
with these substrates the conversion of nitro to nitroso is 
the rate determining step in the reduction sequence. Several 
nitro-reducing systems have been described.
At leasttwo, possibly three or four, separate systems 
•> exist in mammalian liver and another occurs in micro-organisms,
(iv) Mammalian Liver Nitro-reductase
Fouts and Brodie (1957) reported that nitro­
reductase in liver is localised in the soluble and microsomal 
fractions, requires NADPH as cofactor and is inhibited by 
oxygen. NADH was less effective in catalysing nitro reduction.
u m e x x e  ex_ ai v.iyoo; iouna xnax lormaxion 01 xne primary amine
in vitro from p-nitrobenzoate occurred almost exclusively in the
microsomal fraction. The microsomal reductase activity paralleled
cytochrome P-450 concentration, required high levels of NADPH for
maximal activity (Carlson and Dubois 1970), was stimulated by
pretreatment with phenobarbitone or 3-methylcholanthrene (Kato
et^  ^ 1^  1969) and DDT (Carlson and Dubois 1970), and was inhibited
by carbon monoxide and oxygen. NADH linked activity was negligible
in microsomes (Kato et_ al_ 1969). Gillette (l97l) inferred that the
oxygen sensitivity of microsomal nitro-reductase is due to '
competition between oxygen and nitro compounds for reduced cytochrome
P-4 5 0 and suggested that cytochrome P-450 mediated reduction in vivo
would be inefficient as the affinity of the reduced cytochrome for
oxygen is very high (K <0.lp,M).
m
Kato et^  al_ (19^9) reported that the soluble fraction of 
liver contains an enzyme that reduces p-nitrobenzoate to p-hydroxy- 
aminobenzoate and which requires either NADPH, or NADH. Morita et_ al
(1971) found that the schistosomicide niridazole, a nitrothiazole,
\
was reduced by the soluble fraction under anaerobic conditions. 
Hypoxanthine was more effective than NADH as an electron donor and 
NADPH much less effective and the reduction was subsequently shown 
to be catalysed by xanthine oxidase*. This enzyme did not reduce 
p-nitrobenzoate, as measured by uric acid formation from hypoxanthine 
under anaerobic conditions, and the reduction observed by Kato et al 
(1969) may be due to a distinctly different system, although Symms 
and Juchau (l9 7l) claim that p-nitrobenzoate is_reduced by xanthine 
oxidase. Reduction by soluble components is far less sensitive to 
oxygen and Kato et al (1969) suggest that nitro compounds which are 
reduced in vivo are probably reduced to hydroxylamines by soluble
enzymes which may then be reduced by the microsomes to primary 
amines.
Carlson and Dubois (1970) found far.higher levels of 
nitro-reductase activity in the soluble fraction of rat liver 
than in the microsomes. They also reported that the activity of 
this fraction was unaffected by enzyme inducing agents, confirming 
a report by Kato and Oshima (1968). More importantly, they 
demonstrated that when rats pretreated with the enzyme inducers 
DDT and phenobarbital were injected with p-nitrobenzoic acid, 
the excretion of reduced products was no higher than in untreated 
controls.
(v) Semi-nonenzymatic Reduction
Fouts and Brodie (1957) found that high concentrations 
of FAD, FMN and riboflavin stimulated p-nitrobenzoate reduction by 
liver preparations. Kamm and Gillette (1963) later showed that 
FAD was reduced under anaerobic conditions by NADPH-cytochrome c 
reductase which then reduced p-nitrobenzoate non-enzymatically. 
However, the relatively low flavin concentrations found in animal 
tissues suggest that this.mechanism would be unimportant in living 
animals. ■
(vi) Reduction of Nitro Groups in vivo
The reduction of aromatic nitro compounds to nitroso 
and hydroxylamino derivatives in vivo presents a potential 
tdxicological hazard as some of these derivatives are very 
effective methemoglobin forming agents (Kiese 1965)*
Phenylhydroxylamines are also believed to be oncogenic (Gillette,
1971).
Although nitro groups may undoubtedly be reduced in vivo
it seems impossible to predict with certainty whether or not 
reduction will in fact occur. Williams (1959) noted a degree 
of correlation between the amount of reduction that occurred 
with various compounds in rabbits and the overall rate of 
excretion which suggested that compounds which are readily 
excreted are unlikely to undergo extensive reduction.
The situation is complicated in vivo by the activities 
of the intestinal microflora, a subject which has been well 
reviewed by Scheline (1968). Organisms such as Bsch. coli and 
Proteus vulgaris, ubiquitous members of the enterobacteriaceae, 
possess nitro-reductase systems. The reductase of Esch. coli 
which reduces a number of aromatic nitro compounds differs 
sharply from mammalian systems." It is NAD dependant, requires 
manganese ions and a sulphydryl donor and is not inhibited by air 
(Saz and Slie 1954a, 1954b). Thus slowly absorbed drugs may be 
reduced in the gut prior to absorption or excretion in the faeces 
and those compounds which are rapidly absorbed may later come 
into contact with the intestinal flora through biliary excretion 
and then be reduced. This last applies with equal force to drugs 
given parenterally.
(vii) The role of micro-organisms
If nitro reduction in liver is an inefficient process 
as has been suggested by Williams (1959) and by Gillette (1971) 
it is probable that reduction by micro-organi'sms is potentially 
of more importance in vivo.
Glazlco et al (1949) administered chloramphenicol 
parenterally to rats. They observed biliary excretion of large 
amounts of inactive nitro compounds, which were then reduced by
the gut microflora to amines and excreted in the faeces. Very- 
little reduction apparently occurred in the liver. The 
insecticide parathion is not significantly reduced in rats or 
dogs (Ahmed et al 195^) but in ruminants large quantities of 
aminophenols were excreted in the urine (Cook 1957), the reduction 
apparently occurring in the rumen through the action of the 
microflora.
In most instances when reduction in vivo of nitro 
compounds has been reported, it is impossible to conclude that 
reduction could not be due principally to the gut microflora.
An exception is the report by Carlson and Dubois (1970), who 
recovered 25% of an intraperitoneal dose of p-nitrobenzoic 
acid from the rat urine as p-aminobenzoic acid. This substance 
is not biliary excreted in rats (Abou-El-Makarem et al 19&7)*
It is difficult to imagine that specific mammalian 
enzyme systems could have evolved to reduce nitro compounds as 
such compounds are not widely distributed in nature. What is 
more probable is that some nitro compounds, especially those with 
relatively long in vivo half-lives, can act as accidental electron 
acceptors for enzymes normally concerned with intermediary 
metabolism, such as the flavoproteins xanthine oxidase and aldehyde 
oxidase.
In conclusion, the following points are worth emphasising 
That reduction of nitro groups in vivo can occur in liver.
That the potential role of the intestinal microflora is probably 
greater than that of the liver. •
That the extent to which nitro compounds are reduced in vivo is 
unpredictable and is determined by such factors as route of 
administration, ease of excretion and route of elimination.
CHAPTER TWO
The Metabolism of 2~Isopropylaminomethyl-6~Methyl-7~Nitro-
1,2,3,4-Tetrahydroquinoline (Methamniquine*) in the Rabbit and Other
Mammals
Introduction.
Experimental•
(a) Reference Compounds.
(b) Animals.
(c) Chromatography.
(d) Analysis.
(e) Isolation of Metabolites.
Results and Discussion.
Methamniquine is not an officially approved generic name. It 
has been coined by the author merely for ease of reference.
1.
2.
Introduction
Human schistosomiasis is caused by three different species 
of trematode of the genus Schistosoma.
Schistosoma haematobium (Bilharz 1852)
Schistosoma mansoni (Sambon 1907)
Schistosoma japonicum (Katsurada I9O4)
The geographical distribution of S. haematobium is chiefly the 
African continent and parts of the Middle East. S. mansoni is less 
common in Africa but occurs in many areas of Central and South America 
where S. haematobium is not found, whilst S. japonicum is restricted to 
East Asia. The disease affects an estimated 2^0,000,000 people and 
whilst not generally of an acute nature it is greatly debilitating and 
results in an enormous loss of man-hours annually. The control of the 
disease is therefore of great socio-economic importance.
The first schistosomicide, discovered in 1918, was potassium 
antimony tartrate (tartar emetic), a trivalent antimonial, and although 
antimonials are still widely used, the side effects are often severe and 
treatment is lengthy. During the past years many non-antimonia1
compounds have been tested for activity but no schistosomicide of high 
potency and low toxicity has yet been found.
During the 1930’s Mauss (1948) synthesised a number of xanthone 
derivatives which were active against experimental schistosome infections 
in mice (Kikuth and Gonnert, 1948) and proved of value in human medicine. 
These became known as the Miracil series. The first of these active 
compounds was Miracil A (2.1) but the greatest activity was observed with 
Miracil D (lucanthone) (2.2) where oxygen was replaced by sulphur.
nhch2ch2n (c 2h ;)2 NHCH CH N(C Hr ) n 2 2 2 5 2
(2.1) (2.2)
The structural feature found necessary for biological activity 
in this class of compounds is a dialkylaminoalkylamino group para to a 
methyl group on an aromatic ring (Kikuth and Gonnert 194^, Mauss 194^1 
Archer and Suter 1952) and in 1956 Mauss et al reported the development 
of a new and simpler series of active compounds retaining this feature, 
the Mirasans, of which Mirasan (2 .3 ),was the most active.
CH
Cl
NHCH CH N( C_H )_ 2 2 2 5 2
(2.3)
Cl
CH CH_N( C_H )
(2.4)
This series was more active than Miracil D in mice but unlike 
that compound displayed no activity against infections in primates.
In pursuance of this theme Mauss et al (1956) synthesised some tetra- 
hydroquinolines (2 *4 ) which proved very active in mice and also showed 
some efficacy in monkeys, but lacked convincing activity in man. The 
schistosomicidal activity of these three classes of compound has been 
well reviewed by Standen (1963)*
Examples are known of structural modifications in biologically 
active compounds to give a constrained molecular conformation without 
loss of biological activity (Barlow 1964) an<* as an extension of this 
principle Baxter and Richards (1971) synthesised a series of 2-amino- 
methyl tetrahydroquinolines which represent a new class of cyclic 
analogues of Mirasan. The most promising compound of this series to 
emerge from initial screening was 2-isopropylaminomethyl-6-methyl-7~ 
nitro-lt2t3t4”‘tetrahydroquinoline (Richards and Foster 1969» (2 .5 )) 
which was active against mature infections in both rodents and vervet 
monkeys (Foster et al 197l)«
(2.5)
This chapter describes the results of some metabolism studies 
which were carried out in conjunction with the toxicological and 
teratological evaluation of this compound.
EXPERIMENTAL
a) REFERENCE COMPOUNDS
2-Isopropylaminomethyl-6-inethyl~7~nitro-l, 2, 3* 4~tetrahydroquinoline
(Methamniquine)
Methamniquine was supplied on request from the large-scale.
preparative laboratories of Pfizer Ltd* The compound has been synthesised
by three different routes as described by Baxter and Richards (1971)* A
summary of one route is given below.
A solution of 6-methylquinoline-2-carboxylic acid was refluxed
with PCI in dry toluene and the red solution obtained was then reacted 
5
with an ice-cooled solution of isopropylamine in dry toluene to yield
2-isopropyl-carbamyl-6-methylquinoline as a brown mobile oil, a sample
of which was recrystallised from petrol ether (b.p. 60-80°). This
compound was then reduced with LiAlH and subsequently hydrogenated over
4
Raney nickel. Fractional distillation of the crude oil gave 2-isopropyl-
aminomethyl-6-methyl-l,2,3,4“tetrahydroquinoline as a yellow viscous oil.
This was then nitrated with a solution of HNO in H SO . The reaction
3 2 4
mixture was made basic, extracted with CH Cl , and the organic layer 
then evaporated to give a red oil. The oil was treated with one 
equivalent of maleic acid to give the crude hydrogen maleate salt of 
2-isopropyl-aminomethyl-6-methyl-7-nitro-l, 2;, 3i A-tetrahydroquinoline 
which was recrystallised from EtOH/EtOAc. The final product m.p.
187-189° was shown to contain less than 1% of the 5~nitro isomer by 
gas-liquid chromatography.
6-Hydroxymethyl-2-isopropylaminomethyl-7-nitro-l, 2, 3* 4‘~tetrahydroquin- 
oline (Oxamniquine) was supplied on request from the source quoted 
above. It was prepared by microbiological oxidation of 2-isopropyl- 
aminomethyl-6-methyl-7-nitro-l,2,3,4"'tetrahydroquinoline using a strain
of Aspergillus sclerotiorum obtained from the Central bureau voor 
Schimmel cultures, Baarn, Holland (No. 549*65) as reported in a 
patent granted to Pfizer Ltd. (BP II66538* 1969).
2-Aminomethyl-6-methyl-7-nitro-l,2,3,4-tetrahydroquinoline and
7-Amino-2-isopropylaminomethyl-6-methyl-l,2,3? 4~tetrahydroquinoline 
trihydrochloride were obtained from Dr. R. Baxter of the Chemical 
Research Department, Pfizer Ltd.
C~^C]-2-Isopropylaminomethyl-6-methyl-7-nitro-l,2.3*4~ietrahydro~ 
quinoline. The compound was specifically labelled with ^^C at the 
alpha carbon atom of the isopropylaminomethyl sidechain, the label being 
introduced at the initial stage of synthesis via K^^CN in a Reissert 
reaction on 6-methylquinoline to give 6-methylquinoline-2-carboxylic -
acid. The synthesis was completed by the route described earlier.
Specific activity: 1.0pCi/mg.
O
C H]-2-Isopropylaminomethyl-6-methyl-7-nitro-l42,3<4~tetrahydro- 
quinoline. The tritium label was introduced immediately prior to the 
nitration step by the Wilzbach (1957  ^ catalytic exchange process on 2- 
isopropylaminomethyl-6-methyl-l,2,3,4“'fcetrahydroquinoline an(* was 
carried out at the Radiochemical Centre, Amersham, Bucks. The final 
product after nitration had a specific activity of 1 3.9y«Ci/mg. 
DERIVATISATION METHODS 
Methylation
Methyl.esters-of some carboxylie acid metabolites and reference 
compounds were prepared by treatment with an excess of a freshly distilled 
ethereal solution of diazomethane. The method of preparation of 
diazomethane was that given by Vogel (1957)*
A solution of potassium hydroxide (2g) in water (3ml) and 
ethanol (1 0 ml) was heated in a distillation flask at 60-65°, and a
solution of p-tolylsulphonylmethylnitrosainide (8 .6g) in dry ether 
(50ml)'was added dropwise at approximately the same rate as the 
distillation of diazomethane which was collected in two connected 
receivers cooled in an ice-salt mixture. Great care was taken to ensure 
that ether was always present in excess throughout the distillation which 
was continued until the distillate became colourless. Solutions of 
diazomethane were stored at 4° and used for up to one week from the day 
of preparation. \
b) ANIMALS
Methamniquine was administered orally to monkeys, dogs, rabbits, 
rats, mice and hamsters. The species and strain used, sex,weight range 
and dose levels employed are summarised in Table 2*1. All dose levels 
quoted are for methamniquine monomaleate. The compound was formulated 
as a suspension in cremophor El (25% v/v) in physiological saline 
(0 .85% w/v) for administration by stomach tube to monkeys, rats, mice 
and hamsters. Dogs and rabbits received the solid compound by mouth 
in gelatine capsules. Monkeys were anaesthetised by an intramuscular 
injection of phencyclidine before handling.
Rats, mice and hamsters were housed in glass 'Metabowls * 
(Jencons) and monkeys, dogs and rabbits kept in metabolism cages for 
the duration of the experiments with free access to food and water.
Urine and faeces samples were collected at 24-hour intervals. The 
rodents and rabbits were maintained on Spiller-Spratt's small animal 
diet. Rabbits and hamsters were also given lettuce leaves, in the latter 
case to promote an increase in urine volume. Dogs received Spratt's 
dog diet and monkeys were maintained on Haygate's animal diet 41B 
plus bananas, apples, nuts and dates.
Table 2.1
Species/Strain, Sex and Weights of Animals and 
Dose Levels Employed
Animal Species/Strain Sex Weight (Approx) Dose Level 
mg/kg
Monkey vervet CT 2.2kg 5°
Monkey rhesus d 6.0kg 120 and 60
Dog beagle d 10.0kg i5 '
Rabbit N.Z. white 9 3.0kg 400
Rat Wistar Albino cr/9 250-350g 200
Mouse Charles River d 25-359 125
Hamster Syrian d 80.Og ‘ 100
c) CHROMATOGRAPHY - /
Thin Layer Chromatography
Separations of metabolites and comparison of Rf values with
authentic markers were carried out on commercially prepared plates of
silica gel F ,  layer thickness 0.25nmi# (E. Merck, Darmstadt, Germany).
.254 ■
Developing solvents employed were:-
A. Benzene-methanol-aq. ammonia sp.gr. 0.88 (80:20:1 by vol.)
B. Chloroform-triethylamine (9»1 v/v)
C. Ethyl acetate-triethylamine (9:1 v/v)
D. Chloroform-acetic acid (9*i v/v)
E. Methylisobutylketone-formic acid-water (2:1:1 by vol. upper
phase)
F. Butan-1-ol-acetic acid-water (60:15:25 by vol.)
G. Methanol-diethylether (l:l v/v)
Locating Reagents
A. Dragendorff's Reagent (Munier and Macheboeuf 1951)
Soln. A. Bismuth subnitrate (0.85g) in acetic acid 20% (v/v) 
aq. soln. (^Oml).
Soln. B. Potassium iodide 4P% (w/v) aq. solution.
A stock solution was prepared by mixing equal volumes of A 
and B. For use the stock solution was diluted with acetic acid (2 parts) 
and distilled water (1 0 parts).
*\
Column Chromatography
Silica gel. Separation of an acid metabolite was effected by 
adsorption chromatography on a column of silica gel (Hopkin &'Williams, 
M.F.C. grade). The gel was slurried in an excess of benzene and stirred 
for one hour to remove air bubbles, before packing of columns. The 
columns were routinely eluted with 2 -3 bed volumes of benzene before 
use to remove fines.
Sephadex LH 20. Some metabolite separations were carried out 
on columns of Sephadex LH 20 gel (Pharmacia Uppsala, Sweden). These 
gels are long chain polysaccharides with differing degrees of cross- 
linking. The LH 20 gel can be used with organic solvents, and columns 
were routinely prepared by slurrying the gel in methanol. The slurry 
was allowed to stand three hours to permit complete solvent regain 
before packing into columns,
d) ■ ANALYSES 
Spectroscopic Analysis
Ultraviolet and Visible Light Absorption spectra were recorded on a 
Unicara SP 800 split-beam recording spectrophometer. Optical density 
measurements were made on a Unicam SP 5^0 instrument.
Infra-red spectra were recorded on Perkin-Elmer instruments (Infra­
cord 137 or 237)•
Nuclear Magnetic Resonance spectra were recorded on a Varian A60 
instrument. The sweep width routinely employed was 2^0 Hz.
Low Resolution Mass Spectra were obtained on an M.S. 12 mass 
spectrometer (Associated Electrical Industries). The ion-beam 
energy routinely employed was 70 eV. Materials were introduced into 
the ion source by direct insertion probe, either as crystalline solids 
or by evaporating onto the probe tip material eluted from silica gel 
plates.
Radiochemical Analysis -
Urine samples and organic extracts were assayed for radioactivity 
by liquid scintillation spectrometry at 0°. Two spectrometers were 
routinely used, a Nuclear Chicago Mark 1 instrument and a Unilux II 
from the same manufacturer. Counting efficiencies were determined by 
external standardization, and the use of standard calibration curves, 
prepared by plotting the change in external standard ratio (Channel C/ 
Channel A) against the .observed efficiencies for a series of quenched 
standards (Higashimura, 1962). Counting efficiencies varied between 
20-45% for tritium and 60-80% for Carbon-1 4. Samples were routinely 
counted for 10 minutes or for the assembly of 10,000 counts. The 
spectrometer settings used are given in Table 2.2.
Table 2 .2
Instrument Mark I Unilux II
Channel A B C A B C
Upper Discriminator 9.90 9.9.0- 9.90 9.90 9.90 9.90
Lower Discriminator 0 .5 0 0 .5 0 0 .5 0 O.5O 0 .5 0 0 .5 0
Attenuator B + 300 D + 800 E + 100 A + 200 D + 200 E + 0.00
Three scintillation fluids were routinely employed.
A. PPO (2,5“diphenyloxazole) 4«0g
Dimethyl POPOP (1,4-bis-2-[4~Me-5-phenyloxazolyl]] benzene) 0*3g -
N.E. 520 solubiliser (Nuclear Enterprises) 100ml
Toluene 1000ml
B. N.E. 250 (A dioxan based liquid scintillator commercially 
available from Nuclear Enterprises, Edinburgh 11, Scotland.
C. PPO „
5-0g
POPOP 100.Omg
Phenylethylamine • 270ml
Methanol 270ml
Toluene 460ml
Urine samples and organic extracts were counted in scintillator
O II
A. Faeces (freeze-dried) were combusted to H O  or CO , according tocL dk
the isotopic labelling, and the labelled products counted in scintillators
B or C respectively.
• • ■ 3
For determination of radioactivity ( H) on the plate chroma­
tograms, areas of silica corresponding to metabolites were removed by 
scraping and pelleted with a little sucrose in filter paper and combusted 
prior to liquid scintillator spectrometry. Alternatively, plates were
scanned for radioactivity using a Berthold/Desaga plate scanner when 
quantitative determinations of metabolites were made by cutting of 
peaks and weighing,
e) ISOLATION OF METABOLITES 
Extraction procedures
Urine samples were fractionated according to the extraction 
scheme shown in Fig, 2^1.
Faeces were freeze-dried and extracted in a soxhlet apparatus 
with a) hexane and b) methanol.
Enzyme Hydrolysis
Urine samples (3 .Oml) were adjusted to pH 5*0 and buffered 
by dilution with an equal volume of 0.1 M phosphate buffer at pH 5*0.
The diluted samples were then divided into two equal portions, to one 
was added 2,000 Fishman units of (3-glucuronidase obtained from Helix 
pomatia (Sigma Chemical Co.), the second served as a negative control.
A third tube containing phenolphthalein glucuronide plus enzyme was 
set up as a positive control. All tubes were incubated at 37° for 18 
hours.
Isolation of Metabolite III from Vervet Monkey Urine
The carboxylic acid fraction of vervet urine was examined by 
thin layer chromatography in three solvents, D, E and F .[chloroform- 
acetic acid (9*1 v/v), E, methylisobutylketone-formic acid-water (2:1:1 
by vol. upper phase) and F, butan-l-ol-acetic acid-water (6 0:1 5 :2 5 by 
vol.)]. Resolution in all three systems was extremely poor due to the 
presence of excessive amounts of a brown gum. The extract was> therefore 
dissolved in a little hot benzene, applied to a column of silica gel 
(25 x 2cm.), and the column then eluted with benzene 100ml followed by 
chloroform. Continuous elution with chloroform was seen to separate
Isolation of Metabolites 
Extraction procedures
Urine samples were fractionated according to the following extraction 
scheme:
URINEj
jiH 12.0 EtOAc x 3
BASES * NEUTRALS
pH 3 .(TEtOAc x 3 ~ |
PHENOLS
sat. NaHCO x 3 "!
I 
I
-   __
pH 3*0 n-butanol x 3
[ polar ACIDS
I
I
j Aq. RESIDUE!
pH 3.0 EtOAc x 3 ~ ’ 1
I
I
To waste [ CARBOXYLIC ACIDS"]
Fig. 2.1
The organic phase moves always to the left in the flow diagram.
a yellow band from the brown gum which remained firmly adsorbed at 
the head of the column. This band was eluted with chloroform and 
on evaporation yielded an orange gum.
Trituration of the gum with benzene caused instant crystall­
isation, and the metabolite was readily recrystallised from the same 
solvent to give orange rosettes, m.p. 136-138°.
Isolation of a Basic Metabolite from Acid Hydrolysed Rabbit Urine
A twenty-four hour urine sample from an orally dosed rabbit 
(4OO mg/kg) was extracted with ethyl acetate at pH 12.0 and at pH 3«0* 
The urine was then diluted with an equal volume of 4 M HC1, heated 
under reflux for 18 hours, and re-extracted at pH 3 .0  and pH 12.0 with 
ethyl acetate. The total extract (pH 12.0) was chromatographed on a 
preparative layer plate developed in solvent A and a band corresponding 
in Rf value to methamniquine scraped and eluted with methanol. The 
eluate was re-chromatographed on silica, developed in solvent G and the 
main band again scraped and eluted with methanol and evaporated to 
yield a yellow gum. Methamniquine is not readily crystallised as the 
free base, the gum was therefore dissolved in a few drops of methanol 
and triturated with a half-saturated solution of maleic acid in ethyl 
acetate. A yellow precipitate was obtained which was filtered off and 
recrystallised twice from ethanol as golden-yellow plates.
Found: C, 55.8; H, 6.6 ; N, 11.5%. .
Isolation of Metabolite IV from Rabbit Urine
Thin layer chromatography of the ethyl acetate extract (pH 3*0) 
indicated the presence of at least one other acid metabolite in addition 
to metabolite III but attempts to separate these metabolites from the 
gum by thin layer or column chromatography on silica gel were 
unsuccessful. Sephadex gels which are cross-linked polysaccharides
are usually used to fractionate substances according to their molecular 
dimensions (Porath and Flodin 1959)* However, these gels possess other 
properties which are useful for certain separations and molecules with TT 
electron systems are reversibly adsorbed particularly by those gels which 
are highly cross-linked, provided that their molecular size is small 
enough to permit diffusion into the gel matrix (Gelotte I960), Unionised 
acids are also adsorbed by hydrogen bonding of the acid hydroxyl groups 
to the gel-matrix (Brook and Housley 1969)* ■'
The carboxylic acid fraction of rabbit urine was, therefore, 
evaporated at 37°, redissolved in methanol (2 -3 ml) and the whole 
extract applied to a column of Sephadex LH 20 gel (3 0 x 3 cm) in methanol,. 
The column was then eluted with methanol giving a fast running pale- 
yellow fraction well resolved from a second orange band.
The first fraction was examined by thin-layer chromatography 
and scanned for radioactivity. The only area of radioactivity was 
associated with the yellow material which appeared substantially pure.
The fraction was reduced to small volume and refrigerated overnight at 
4° to yield pale-yellow; crystals. This material corresponded by t.I.e. 
to metabolite V (vide infra) and after one recrystallisation from 
ethanol its co-identity with V was confirmed by a mixed melting point 
determination.
The orange fraction was chromatographed on silica gel and 
developed in solvent system D with metabolite III as a reference marker. 
Two major yellow bands were seen at Rf. 0 .5  and 0.3 both were radio­
active. The faster of these appeared to be metabolite III. The extract 
'in toto1 was then chromatographed on a preparative layer plate, the 
two major bands removed by scraping and the metabolites eluted into 
methanol.
The faster of the two metabolites was easily crystallised 
by trituration with benzene after evaporating off the methanol and 
confirmed as III by co-chromatography with authentic III in two 
further solvents; E and F.
The slower material on evaporation yielded an orange-brown 
gum which could not be crystallised. It was treated with an excess 
of diazomethane in ethereal solution and again chromatographed on a 
preparative silica layer developed in solvent G (ethyl acetate- 
isopropylamine 19:1 v/v). The major band eluted with methanol, gave 
on evaporation a red solid which was recrystallised twice from ethyl 
acetate/cyclohexane to give orange rods (2 2.1mg) m.p. 125-132°
Found: C, 54»lj H, 5*«4> 'N, 9 *8%. This metabolite was designated 
metabolite IV.
Isolation of Metabolite V from Rabbit Urine
The polar acid fraction of rabbit urine was evaporated to 
small volume by rotary evaporation in vacuo at 50°, and redissolved in 
methanol (3ml). The insoluble salts were removed by filtration and the 
extract applied ’in toto1 to a column of Sephadex LH 20 in methanol 
(3 0 x 3cm). Elution with methanol separated a fast running pale yellow 
diffuse band which was collected and further purified by passage through 
a second column of LH 20 Sephadex. The eluted band now appeared pure 
by t.l.c. in solvent F and after evaporation to small volume it was 
refrigerated overnight at 4° to yield a pale yellow crystalline solid 
which was recrystallised from ethanol, m.p. 271° (uncorrected)
Found: C, 51.2; H, 6.2; N, 12.6 ; Cl, 10.8%
Results & Discussion 
Absorption and Excretion
Urinary and faecal excretion of radioactivity after oral 
administration of - methamniquine was measured in five species.
The recoveries are shown in Table 2 .3 .
Table 2.3
Recovery of Radioactivity % in Urine and Faeces of Five 
Species following Oral Administration of - Methamniquine
Species No. Sex Dose
H»gAg
Urine 
72 hours
‘Faeces 
72 hours
Rabbit 3 9 400 55-1 - 66.4 10.2 - 12.3
Rat 2 cr 200 50.7 - 60.2 17.5 “ 21.0
• 2 9
Mouse 5 * CT 125 35.2 10.3
Hamster 2 * cf 100 64.5 - :
Rhesus
monkey 1 cf 60 26.4 <1.0
* Samples pooled 
Excretion of ^CO
• ' Oxidation of the sidechain of methamniquine gave a metabolite 
(III)*with a ^^C-labelled carboxyl group, which might be decarboxylated 
in vivo. Respiratory excretion of *^C0„ was therefore studied in three' r irnir i— m .
species after intravenous injection of methamniquine. Only small amounts
of radioactivity were expired as ^CO during 24 hours collection
^ -
accounting for 2 .6, 0 .4  and 1.7% of the dose respectively in rabbit, rat
v  The reader is referred to Fig. 2.16 on p.59
and mouse* In another experiment an orally dosed mouse (125 mg/kg) 
expired 2*7% of the dose in 24 hours.
Identification of Metabolite II
The degree of activity of Mirasan and related compounds was 
shown by Rosi et al (1 9 6 7 a, b, c) to be related to the ability of the 
host to hydroxylate the aromatic methyl group and subsequent testing of 
a series of analogues of Mirasan and related xanthenones and their 
hydroxymethyl derivatives clearly demonstrated that hydroxylation 
enhanced schistosomicidal activity in mice and hamsters (Berberian 
et al 1969)•
These observations suggested that methamniquine I (2.5 ) might 
also be metabolised in a similar fashion to give II (2.6),
CH
CH NHCH
CH
HOH C 
2
CH
CH NHCH
0 N 
2 CHH
(2 *5 ) ' (2 *6 )
As the compound was displaying good activity against S. mansoni
infections in vervet monkeys a twenty-four hour urine sample was
obtained from a treated animal (5 0 mg/kg) in order to search for the
hydroxymethyl metabolite. The hydroxymethyl analogue of lucanthone is
excreted largely as a glucuronide (Rosi et al 1967a), therefore the 
urine was divided into two equal portions and one lot incubated with 
P-glucuronidase overnight prior to extraction at pH 12.0 with ethyl acetate.
Thin Layer Chromatography
Extracts (pH 12.0) of untreated and enzyme hydrolysed urine 
were co-chromatographed with authentic samples of I and II on silica 
gel in three solvents, A, B and C. Yellow spots of approximately equal 
intensity and corresponding in Rf value to authentic I and II were seen 
on all three chromatograms and in each case the spot corresponding to 
unchanged drug (i) was located at the higher Rf. On spraying with 
Dragendorff's reagent both spots gave an immediate orange colour. The 
best separation was achieved with Solvent A in which the Rf values of 
I and II were 0 ,6 5 and O .4 5 respectively. It was tentatively concluded 
on this evidence that the faster material was unchanged drug and that 
the second spot was the sought after hydroxymethyl metabolite II. The 
amount of II extractable from urine was not increased by enzyme pre­
treatment.
Chromatography of Acetyl Derivatives
Samples of the monkey metabolite and authentic II were 
acetylated using an acetic anhydride/pyridine mixture, the reaction 
proceeding for 3^ minutes at room temperature. Thin layer chroma­
tography of the products on silica gel developed in solvent A revealed 
three spots on each chromatogram of identical Rf values, providing 
further confirmatory evidence for the identity of the monkey metabolite. 
The slowest of these corresponded to II indicating that the reaction was 
incomplete. The two faster spots were presumably the di and tri-acetyl 
derivatives of II. .
Ultra-violet Spectroscopy
Ultra-violet spectra of the metabolite and authentic II 
were recorded in methanol solution. Both showed a single broad -
band of absorption with a max at 254nm- compared to max at 250 nm 
in the parent drug. A similar small bathochromic shift was also 
noted by Rosi et al (1967c) in hydroxylated Mirasans.
Hydroxylation of Methamniquine in Other Species
Methamniquine was given, orally, at various times to a 
number of other species, namely: rhesus monkey, dog, rabbit, hamster, 
rat and mouse, all of which were found to excrete the hydroxymethyl 
metabolite II in urine. Identification was based on similar evidence to 
that described above. In the case of rabbit (and rat) sufficient material 
was isolated for the recording of an infra-red spectrum (Figure 2.2) which 
agreed in every way with a spectrum of the authentic sample (Figure 2 .3 ) 
thus proving the identity of the metabolite beyond question.
Identification of the Acid Metabolite (III)
The quantity of metabolite isolated from vervet monkey urine 
was only a few milligrams and was insufficient for a full physical 
analysis. Metabolites which appeared to be identical were subsequently 
isolated from the urine of three female rabbits which had received oral 
doses of 4OO mg/kg during teratology studies, and a male rhesus monkey 
which was given three consecutive daily oral doses of 125 nig/kg. Both 
isolates melted at the same temperature as the metabolite recovered from 
vervet urine and mixed melting points were also identical. The yield 
from rabbit urine was 57 m9t Found: C, 55»7? H, 5*3; N, 11.5%;
C11H12N2°4 r8qUireS H’ 5#1; N’
Infra-red Spectrum
An infra-red spectrum (KBr disc) was recorded (Figure 2 .4 )*
The principle assigned absorptions are listed in Table 2i3#
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TABLE 2«3
Assignments of Principal Absorptions
Absorption (cm ~^) Assignment
3400 quinoline > NH stretching
3OOO-23OO bonded -OH stretching of carboxyl
group
1700 (s) > C=0 stretching of carboxyl group
1320 (s) asymmetric -NO stretching
1320 (s) symmetric -NO
The metabolite was soluble in saturated sodium bicarbonate 
(pH 8,0) and therefore was proably a carboxylic acid although the 
possibility of a nitrophenol could not be ruled out on solubility 
grounds as phenols of this type are sufficiently acidic to dissolve in 
bicarbonate solution.
The infra-red spectrum demonstrated conclusively that the 
metabolite contained a carboxyl group (strong absorption at 1700 cm *) 
and also that the nitro group remained intact (strong absorption at 
1320 and 1320 cm ^). The analytical data supported a molecular formula 
of C_.H oN 0 and the structure was tentatively held to be as shown
11 12 2 4 
(2 .7 ).
COOH
Nuclear Magnetic Resonance Spectrum
An nmr spectrum was recorded in deuterochloroform (Fig. 2*5) 
wrhich fully confirmed the assigned structure. The signals and their 
assignments are shown in Table 2*4*
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Table 2 .4
Chemical Shifts and Assignment of Proton Magnetic Resonance Shifts
Chemical Shift (T') H Multiplicity Assignment
2.45 2 Singlet Quinoline > NH^
2.80 1 Singlet Proton at C-8
3.15 1 Singlet Proton at C-5
5.95 1 Multiplet Proton at C-2
7.20 2 Triplet Protons at C- 4
7.55 3 Singlet Protons of aromatic 
methyl group
7.85 2 Multiplet Protons at C-3
Identification of a Metabolite Isolated from Rabbit Urine after Acid
Hydrolysis
The urine of all species appeared to contain large amounts of 
polar drug-related material not extracted by ethyl acetate under any 
conditions of pH and with the discovery during toxicity testing that 
rabbits were able to tolerate relatively high oral doses (4OO mg/kg) 
of the drug without untoward effect, the rabbit was the species of choice 
for studying the nature of these polar metabolites.
It was considered that the polar metabolites would most 
probably be conjugates,accordingly a sample of rabbit urine was 
incubated with p-glucuronidase at 37 and a second sample was heated 
under reflux for 18 hours after dilution with an equal volume of 4£[,
HC1. Incubation with p-glucuronidase did not appear to release any
significant amount of drug-related material extractable with ethyl 
acetate at pH 12.0 or pH 3*0 as judged by thin layer chromatography.
Extraction of urine at pH 12.0 after acid hydrolysis yielded 
a large amount of bright yellow seemingly drug-related material. A 
thin layer chromatogram of this extract, run on silica gel and 
developed in solvent A (benzene-methanol-aq. ammonia S.G. 0.88, 80:20:1 
by vol.) showed the-presence of a prominent yellow spot at the same Rf 
as an authentic sample of unchanged drug. Further chromatograms 
developed in solvents B and C failed to separate the metabolite from 
the marker and it was concluded that it was probably unchanged drug, 
and that it may have been excreted as an N-glucuronide which was not 
hydrolysed by enzyme treatment. These N-conjugates are known to be 
resistant to p-glucuronidase preparations. However, when the metabolite 
was isolated as a crystalline solid its melting point was determined 
and it was found to melt sharply at 179° compared with 186° for meth­
amniquine itself. Analysis for C, H and N gave C, 35*8; H, 6 .6 ; and 
N, 11.5% which were also inconsistent with the calculated percentages for 
methamniquine, although both of these discrepancies could perhaps be 
explained by the presence of impurities in the isolated material.
Mass Spectroscopy
A mass spectrum of the metabolite was obtained (Fig. 2.6) and 
compared with the mass spectrum of methamniquine (Fig. 2.7)* The 
molecular ion peak in the spectrum of methamniquine was seen as expected 
at m/e 2 6 3, however, in the case of the metabolite the molecular ion 
peak occurred at m/e 249, an apparent difference of 14 in mass. In . 
both spectra the base peak occurred at m/e 72 which results from 
cleavage of the basic sidechain of methamniquine as a charged species 
from the molecular ion (CH :+NH.CH.(CH )o = 72).
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Fig 2.6 Simplified mass spectrum of a metabolite isolated from rabbit 
' urine after acid hydrolysis
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j Fig. 2.7 Simplified mass spectrum of methamniquine
There is also a competing initial fragmentation process which results
in prominent fragment ions which again show a regular difference of 14
in mass at m/e 192, 191, 175* 174* 145, and I44 (Fig. 2 .7) and at m/e
178, 177, l6l, 160, 131 and 130 (Fig. 2:6). These ions are formed
sequentially by loss of the side chain followed by loss of the nitro
group in either a one or two-step process each loss confirmed by a
metastable ion peak. The difference in mass was attributed to a loss
of CH which was supported by elemental analysis of the isolated salt. d*
Found: C, 55.8; II, 6 .6 ; N, 11.5% C17H23N3 °6 requires C, 55*9; H, 6.3;
N, .11.556.
Nuclear Magnetic Resonance Spectroscopy
The structural difference clearly did not involve the sidechain 
and the obvious possibility was therefore loss of the aromatic methyl 
group which could easily be spotted by n.m.r. spectroscopy. Spectra 
were therefore recorded of both the metabolite (Fig.2 .8 ) and methamni- 
quine (Fig. 2 .9) in trifluoroacetic acid.
Inspection of the metabolite spectrum shows that the signal for 
the protons of the aromatic methyl group which occurs at 7 «25T i n  the 
spectrum of methamniquine has disappeared and that the pattern of the 
aromatic signals has also changed from an AX pattern to an ABX confirming 
the presence of an additional aromatic proton. The spectrum is in all 
other ways consistent with the proposed structure (2 .8 ).
CH NHCH (CH )
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Origin of the Demethyl Metabolite
The isolation of demethyl methainniquine occasioned some 
speculation as to its possible origin for whereas a wide variety of 
drugs are metabolised by the oxidative removal of O-or-N-methyl groups, 
e.g. the analgesic drug codeine which is metabolised in man by both 
O-demethylation and N-demethylation, the analogous removal of an aromatic 
methyl group is not a recognised route of metabolism.
The oxidation of aromatic methyl groups to carboxyl groups 
by contrast is a well established metabolic route, hence toluene is 
oxidised to benzoic acid (Schultzen and Naunyn 1 867) and numerous 
substituted toluenes such as p-nitrotoluene (Gillette 1959) and 
butylated hydroxytoluene (Wright et al 1965) are also oxidised to 
carboxylic acids. It seemed reasonable then to suppose that oxidation 
of the methyl group of methainniquine might well proceed beyond the 
alcohol (metabolite II) to furnish an acid which could, if it retained 
the basic sidechain, also account for all or part of the polar metabolites 
not extracted with ethyl acetate.
The facile decarboxylation of nitro-carboxylic acids has been 
reported (Franzen and Katonah 1957) and it was tentatively concluded 
that the demethyl metabolite was an artefact formed during the acid 
refluxing of urine probably through decarboxylation of an acid 
intermediate of probable structure (2 .9) which remained in the aqueous 
residue after the initial extractions. .
HOOC
(2.9)
Identification of Metabolite V
The percentage of residual radioactivity in urine after 
extractions with ethyl acetate at acid and alkaline pH was always 
high ranging from 25“35% in rabbits to 65% in a rhesus monkey.
Several methods were tried to extract and isolate the 
residual radioactivity including ion-exchange chromatography and 
lyophilisation followed by derivatisation. The simplest method which 
proved to be most successful led to the isolation of the major 
metabolite. This involved saturation of rabbit urine with sodium 
chloride followed by extraction with n-butanol at pH 3.0, when most 
of the residual activity was partitioned into the organic solvent. 
(The addition of sodium chloride was later found to be unnecessary.)
This extract contained only one radioactive metabolite which 
was isolated as described (Metabolite V).
Mass Spectroscopy ■
A mass spectrum was obtained (Fig. 2.10) which was charact­
erised by a large base peak at m/e 72, easily the most abundant ion 
and indicating an intact sidechain. Other characteristic losses also 
indicated the presence of a nitro group.
The expected molecular ion peak was present at m/e 293 but 
was of very low abundance. The spectrum therefore supported a 
structure as in (2*9)•
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Fig 2.10 Simplified mass spectrum of Metabolite V
Nuclear Magnetic Resonance Spectroscopy
A ri.ra.r. spectrum was recorded in trifluoroacetic acid 
(Fig. 2.11). As is seen in the spectrum of the supposed artefact (Fig. 
2 .8 ) the signal for the protons of the aromatic methyl group which 
occurs at 7 »2 5Yin the spectrum of methainniquine has again disappeared 
from the spectrum, however, the unsplit signals for two aromatic protons 
at 2 .2Tand 2 .65T' now confirm the presence of a substituent in the 6-
position in the aromatic ring. All the signals associated with the 
protons of the si dechain are present confirming the mass spectral 
evidence.
Infra-red Spectroscopy
An infra-red spectrum was recorded (KBr) (Fig. 2.12). A
strong absorption band is seen at I69O cm  ^which is the typical
frequency for the C=0 stretching vibration of an aromatic carboxyl
group. A very broad band of absorption spanning the range 3^00 to..
23OO cm  ^is also a characteristic absorption of carboxylic acids due
to 0-H stretching vibrations in strongly hydrogen bonded molecules.
The combined spectroscopic evidence thus complement each
other and support the proposed structure of V as (2*9)*
Micro-Analysis
Analysis of the sample gave C, 51*2; H,*6.2; Nt 12.6%,
C H N 0 required C, 57-3; H, 6.5; N, 1 4.3%. These figures satisfy 
14 19 3 4
a formula of C H. N 0 HC1 and a subsequent analysis for chlorine
14 19 3 4
gave 10.7% (required 10.8%) confirming the spectroscopic data. The 
extraction of metabolite IV as a salt thus affords an example of the 
extraction of an amine from acid solution by ion pair formation. 
Identification of Metabolite IV
The isolation of metabolites oxidised at C- 6  (II and V) and 
at C- 2  (III) strongly suggested that this metabolite would be either the 
6-hydroxymethyl analogue of III (2 .1 0) or a dicarboxylic acid (2 .11).
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Mass Spectroscopy
A mass spectrum was recorded (Fig. 2.13). An ion of very 
low abundance was seen at m/e 266, the calculated molecular weight 
for the ester of (2.10) but no peak occurred at m/e 294 (Mol. wt« of 
the ester of 2.1l). Major fragment ion peaks occurred at m/e 207, 193* 
l6l, I3 7* 134 and IO5 (base peak). Fragment ions of mass 207 and l6l 
were probably formed sequentially from the molecular ion by loss of 
59 (-'COOMe) and 4 6(-'NO ) but no metastable peaks were present to 
confirm these losses. By contrast metastable ion peaks were present 
confirming the formation of daughter ions m/e 161, 106 and 77 from 
parent fragment ions at 193* 137 and IO5 all losses which could not be 
rationalised. Absence of a peak at m/e 72 indicated a metabolic loss 
of the sidechain but further evidence was required to confirm the 
structure as (2 .10) suggested by mass spectroscopy.
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Fig. 2.13 Simplified mass spectrum of Metabolite IV
Infra-red' Spectrum
An infra-red spectrum was recorded (Nujol mull) (Fig. 2 .14).
A strong absorption at 1720 cm  ^was assigned as the stretching 
frequency of an ester carboxyl group and the absence of any other 
absorption around this frequency provided good evidence for only one 
> C=0 grouping, in accordance with structure (2.10). A relatively weak 
absorption at IO5O cm  ^was probably due to the C=0 stretching vibration 
of a primary alcohol, but was not considered sound enough evidence for 
a positive proof.
Nuclear Magnetic Resonance Spectroscopy
A spectrum was obtained in deuterochloroform (Fig. 2 .I5 ).
The signals and assignments are given in Table 2.5* .
Table 2-5
Chemical Shift (*Y ) H Multiplicity Assignment
2.75 1 Singlet Proton at C-8  (
2 .8 5 1 Singlet Proton at C-5
5*30 2 Singlet Methylene protons of 
-CH OH group
5*90 1 Multiplet Proton at C-2
6 .2 3 Singlet Protons of ester methyl 
group
7 .2  and 7 .8 5 4*5 Multiplets Protons at C-3 and C-Zj. 
plus solvent impurity
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The spectrum is fully in accord with the structure shown below (2 .12).
HOH C
COOMe
(2*12)
confirming the structure of the metabolite as (2.10).
That the assignment of -CH OH and -C00CH to C-6 and C-2
3
respectively are correctly made is witnessed by the absorption signal 
for the methylene protons of the -CH OH group, which occurs as a 
sharp singlet. Had these two groupings been reversed the signal would 
be split by the proton on the adjacent carbon atom (C-2) and occur as 
a 2 proton doublet.
Micro Analysis
Found: C, 54.1; H, 5 .3 ; N, 10.5%, c^12Hi4N2 °5 re<luires 
C, 54.1; H, 5.4; N, 9.854).
Primary Amines
Two metabolites which might have been produced in vivo were 
the 7-amino analogue (2 .1 3) and the primary alphatic amine (2 .I4 ).
Both of these compounds had been synthesised and were available as 
reference markers for chromatography. A search for these two 
compounds was made in extracts of alkaline urine from orally dosed 
animals but in none of the species investigated was either compound 
detected.
Quantitative Determination of Urinary Metabolites
Quantitative determinations of unchanged methamniquine, 
metabolite II and metabolite III were made in the urine of five species 
and are given in Table 2.6.
Table 2 .6
Urinary Excretion of Methamniquine and Two Metabolites in
O
Four Species after Oral Administration of [ H3 - Methamniquine
Species No Sex Dose % Urinary Radioactivity
mg/kg Me thamni qui ne Metabolite II Metabolite III
Rhesus
monkey 1 cS 65, 4-8 5-0 1.9
Rat 2 cf 200 • 4-2 6 .6 <0 .1
Hamster 2* cf 100 0 .8 3.6 6.5'
Rabbit 2 9 400 2 .1 2.9 2 1 .0
* Pooled samples
Metabolite V was not identified until the later stages of this 
investigation and no accurate quantitative determinations of V were made. 
However, the amount of 'desmethyl' methamniquine recoverable after acid 
treatment indicated that it is the major metabolite in all species and 
accounts for at least 40% of the urinary radioactivity.
Discussion
After administration of single oral doses of [^C] - 
methamniquine to rabbits, rats, mice, hamsters and a rhesus monkey, 
urinary recoveries of radioactivity ranged widely from 2 6-66%.
Faecal excretion was also variable, ranging from 21% in a rat to 
<1.0% in a rhesus monkey. This latter figure indicates virtually 
complete absorption, in the monkey and suggests that the higher 
recoveries of radioactivity in the other species may be due to biliary 
excretion. Alternatively, they may reflect incomplete absorption as 
the dose levels employed were all considerably greater than that 
received by the one monkey studied. Excretion of the radiolabel as 
.^CO was a relatively unimportant route of elimination in the species
Ca
studied.
The drug is extensively metabolised in vivo, unchanged 
methamniquine never accounting for >5% of the urinary radioactivity. 
Metabolism occurs by two competing oxidative mechanisms involving 
attack on the aralkyl sidechain and/or the alkylaminoalkyl sidechain.
The major metabolite in all animals is an amphoteric species (V) (see 
Fig. 2.16) in which the 6-methyl group has been oxidised to a carboxyl 
group. No accurate quantitative determinations of V were made, but it 
was estimated that V accounts for at least 4°% of the urinary radio­
activity recovered from each species. The conversion of I to V involves 
an alcohol intermediate (II) which has been isolated and identified.
This intermediate was synthesised and displayed a greater degree of 
schistosomicidal activity than I on a weight for weight basis (Foster 
et al unpublished results). Thus,hydroxylation of the aromatic methyl 
group is an activating step which parallels the activation of lucanthone
(2.1) and other Mirasan analogues (Rosi et al 196?a, b). The further
-59-
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Fig. 2>16. Metabolic pathways of methamniquine
1/
oxidation of II is in sharp contrast to the metabolism of hycanthone
(2 .1 5), the alcoholic congener derived from lucanthone, which undergoes 
sulphoxidation and N-dealkylation but is not attacked at the hydroxy- 
methyl grouping (Hernandez et al 1971)•
0 HNCH CH N(C H )
CH„OH
(2 .15)
Instead, conjugation with glucuronic^acid occurs, a sythesis which 
apparently does not take place in the case of II#
Oxidation of the aliphatic sidechain to a carboxylic acid 
(III) is an alternative route of metabolism of secondary importance#
The extent of excretion of III varied with species, rabbit, hamster 
and rhesus monkey excreting 2 1#0 , 6 .5  and 1.9% in urine respectively, 
although these figures are not strictly comparable due to differing 
dose levels. This acid also appears in the urine of dogs and mice 
(qualitative determination only) but was not found in rat urine on 
numerous occasions after moderately high doses either by t.l.c. or by 
g#l.c. after derivatisation (methylation). In this respect the strain 
of rat used seems to be important. This work was carried out in Vistar 
rats (Ash Laboratories, Manston, Kent), however, on one occasion recently 
when methamniquine was dosed to a Charles River rat (Sprague-Dawley 
derived), some III was found in the urine. Metabolite III had no 
schistosomicidal activity against experimental infections in mice 
neither when administered orally nor by a parenteral route.
A third acidic metabolite (IV) in which oxidation has taken 
place at both ends of the molecule was isolated from rabbit urine.
No specific search for it was made in the urines of other species.
The primary aromatic amino analogue of methamniquine was not 
found in the urine of any species and it is probable that reduction of 
the nitro group is not an important route of metabolism.
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Introduction
The enhanced schistosomicidal activity displayed by the 
hydroxymethyl metabolite of methamniquine and its ready large- 
scale synthesis by microbiological oxidation led to a cessation 
of interest in its parent drug. The more potent compound 
(oxamniquine) was selected for further development,and metabolism 
studies were initiated to furnish data complementary to the toxicity 
data required for submissions to the various regulatory bodies 
concerned with new drug development. These studies were greatly 
facilitated by the experience gained.with methamniquine and the 
results of these studies are embodied in this chapter.
EXPERIMENTAL
REFERENCE COMPOUND
3 O
C H3 - Oxamniquine. A further batch of [ H] - methamniquine 
was synthesised by the method outlined in chapter II. It was isolated 
as the methane sulphonate salt and had a chemical purity of 99%«
This was then converted to oxamniquine by microbiological oxidation 
as described previously. The final product was 98% pure radiochemically 
with a specific activity of 110.8 p,Ci/mg.
ANIMALS
o
[ H] - Oxamniquine was administered orally to dogs, rabbits, 
rats, mice, hamsters and a rhesus monkey. The species and strain used, 
sex, weight range and dose levels employed are summarised in Table 3*1. 
All dose levels quoted are for oxamniquine free base. The compound was 
formulated as a suspension in Cremophor El (25% v/v) in physiological 
saline (0 .83% w/v) for administration to rats, mice and hamsters.
Dogs, rabbits and the rhesus monkey received the solid compound by 
mouth in gelatine capsules. All animals were housed and fed as 
described previously.
Unlabelled oxamniquine was also administered to a group of human 
volunteers (5 ) by intramuscular injection. Each volunteer received 
800 mg of the free base, the dose levels varying between 10 -1 3 mg/kg.
Table 3-1
Species/Strain, Sex and Weight of Animals and 
Dose Levels Employed
Animal Species/Strain Sex Weight
(approx)
Dose Level 
mg/kg
Monkey rhesus 9 3 .4kg 95
Dog beagle 9 1 0.0kg 60
Rabbit N.Z. White 9 2.5 - 3.5kg 200 and 4OO
Rat Wistar albino cf 250-350g 6°
Mouse Charles River 9 25.35g 400
Hamster Syrian cf 8 0. Og 60 and 90
ANALYSES .
Oxamniquine assay
Oxamniquine was assayed in serum samples as its trimethylsilyl 
ether derivative by a gas-liquid chromatographic method.
Column and operating conditions
The instrument used was a Varian 1200 (Varian Associates, 
Walton-on-Thames, Surrey) fitted with a flame ionisation detector.
The column was of glass, 5' in length x l/8 " external diameter, 
packed with H.P. Chrome W 100-120 mesh coated with DC-56O, a p-chloro- 
phenylmethyl silicone (5% v/w) as the stationary phase. The operating 
temperatures were: injection port 230°, column oven 210°, detector
25P°. The carrier gas was nitrogen (whitespot) at a flow rate of 
25 ml/min.
Extraction Procedure
Serum samples, optimally ml minimum, were made basic 
with a half volume of M-NaOH, extracted twice with equal volumes 
of diethyl ether and the extracts dried over anhydrous sodium 
sulphate.
Internal Standardisation
The internal standard (^ P-g) was added■ wi'th thorough mixing 
after the dessication stage. This was either octacosane ^ 2 8  ^ °r 
heptacosane (C ). Extracts with added standard were then evaporated 
to dryness under a stream of nitrogen.
Silylation Procedure
The method used was that developed by Sweeley et al (1963)* 
The extract was dissolved in dry pyridine (0.2 ml) and after addition 
of hexamethyldisilazane (0.1 ml) and trimethylchlorosilane (0 .0 5  ml) 
the mixture was allowed to stand in a stoppered test tube for ten 
minutes at room, temperature. Pyridine is troublesome in the chromato­
graph overlapping peaks with short retention times and Wood et al 
(1965) removed pyridine prior to chromatography of monoglyceride 
ethers by aqueous washes. The reacted samples were therefore taken 
up in ether (5 ml) and washed three times with distilled water which 
successfully removed the excess pyridine without hydrolysis of the 
TMS derivative.
Column Calibration
Standard amounts of oxamniquine and n-alkanes were mixed 
and silylated as described. The peak height ratios were calculated 
after g.l.c. and plotted against known weight ratios. A linear 
response was obtained with amounts of oxamniquine up to 24p-g.
Assay of Urinary Aromatic Amines
Urinary aromatic amines were assayed using the diazo test 
of Bratton and Marshall (1939)* Urine (0,2 or 0.5 ml) was diluted 
to 3*0 ml with distilled water and acidified with 3M HC1 (0,5 ml).
Sodium nitrite (0.5 ml of a 0.1% w/v aq. solution) was then added and 
the mixture allowed to stand for three minutes before adding ammonium 
sulphamate (0.5 ml of a 0.5% w/v aq. solution) to destroy any excess 
nitrous acid. After another three minutes sodium acetate (0.2 ml of 
a saturated aqueous solution) were added followed by the coupling 
reagent (0 .5  ml of a 0.1% w/v aqueous solution of N-l-naphthylethyl- 
enediamine). Four hours were allowed for full colour development at 
which time the estimations were measured at 54P nm using a Unicam:
SP 500 spectrophotometer. A calibration line was prepared by 
diazotisation and coupling a series of standard solutions of anthranilic 
acid covering the range 0.0 to 0.2 pmoles.
CHROMATOGRAPHY AND SPECTROSCOPY
Details of instrumentation and techniques were as previously 
described (cf Chapter II). One additional chromatographic locating 
reagent was used for detection of acyl derivatives of glycine, i.e. 
hippuric acid type metabolites.
■ ?
Spray Reagent
p-Dimethylaminobenzaldehyde 4% (w/v) in acetic anhydride 
containing a few crystals of sodium acetate (Gaffney et al 1954)*
After spraying, plates were heated for 1-2 minutes at 150° when hippurate 
gave a deep orange colour.
Radiochemical Analysis;
Tritium Exchange
Two methods were used for determining tritiated water 
in urine and plasma samples.
(a) Direct method (urine only) by counting of water 
distilled from urine samples in vacuo.
(b) Indirect method by difference of counts before and 
after lyophilisation and reconstitution of samples to 
their original known volumes with distilled water.
Blood Radioactivity
Radioactivity determinations on whole blood samples were made 
by combustion of duplicate samples (2O-5O pi) pipetted onto filter 
papers (Whatman No. l) after thorough drying using a hot air blower.
RESULTS AND DISCUSSION 
Absorption and Excretion of Oxamniquine
The urinary and faecal excretion of radioactivity after oral
O
administration of [ H] - oxamniquine was measured in six species. The 
recoveries of radioactivity are shown in Table 3»2. The relatively low 
recovery of radioactivity in faeces indicates good absorption in all six 
species. The highest faecal recovery was 21% in a rat. The bulk of this 
(18%) was excreted in the first 24 hours after dosing, and could therefore 
be due to unabsorbed drug but is more probably due to biliary excretion 
as the rat is known to be a good biliary excretor (Abou-El-Makarem 1967b). 
Recoveries in the other species, mouse excepted, are all considerably 
lower than in rat.
Table 3 *2
Recovery of Radioactivity % in Urine and Faeces of Six Species 
following Oral Administration of fyH] - Oxamniquine
Species No Sex Dose Urine Faeces
mg/kg % Time
(Hrs)
% Time
(Days)
Dog 2 9 60 38.2  (3 6 . 4 - 4O.O) 72 4-1 7
Rat 3 cr 60 42.9  (3 2 .0 -5 5 .8 ) 72 21 .4 7
Rhesus
monkey 1 9 95 4O.9 72 8 . 0 7-
Hamster 4
2 x 2
cf 6 0 /9 0 45.9 (4 4 .0 -4 7 .7 ) 72 - -
Mouse 5
pooled
9 4 0 0 49.4 72 14.9 6
Rabbit 1 9 4 0 0 27.5 48 8 .1 3
Rabbit 1 9 270 29.7 48 4 .9 2
Oxamniquine Assay
Methamniquine has been successfully assayed by a gas-liquid 
chromatographic method (Kaye and Woolhouse 1972) and it was thought 
that a sensitive assay for oxamniquine might also be developed along 
the same lines. However, when oxamniquine was chromatographed on a 
silicone-coated column of medium polarity (5% F.60 on gas-chrome Q) 
multiple peaks emerged probably indicative of thermal instability.
The compound was then acetylated with an acetic anhydride/ 
pyridine mixture and rechromatographed, but again multiple peaks were 
seen with shorter retention times which suggested that the reaction was 
not quantitative under the conditions used. -
It was then decided to try chromatography of a silyl derivative. 
The general order of decreasing ease of silylation of proton acceptor 
groups is: alcohols (primary, secondary then tertiary), phenols,
carboxylic acids, amines (primary, secondary) and amides (Pierce 1968). 
Oxamniquine has one primary alcohol function and two secondary amine 
groups and it was therefore hoped that the alcoholic-OH could be silylated 
both quantitatively and selectively. Oxamniquine was silylated as 
described in experimental and gave only a single peak when chromatographed. 
The derivatisation procedure was completed in ten minutes and it was 
thus assumed that only the ether derivative had been formed. A method 
of assay for oxamniquine was developed based on this procedure which 
. was used to measure drug levels in plasma/serum samples from dogs, 
rabbits and mice in toxicity trials also in human volunteers. This 
method was sufficiently sensitive to determine the drug at concentrations 
of 0 .2 5 pg/ml in plasma/serum where a minimum sample of 3 ml was' 
available.
Efficiency of Recovery
The overall efficiency of the assay method was determined 
for a series of spiked dog serum samples covering the range 1.6 to 
10.0 p,g/ml. The mean recovery was 65% and a. correction factor has 
been applied in all cases where measurable amounts of drug were found 
irrespective of species.
Serum Levels of Oxamniquine in Rabbits v
Rabbits (N.Z. White), two of each sex, received intramuscular 
injections of the drug at l±00 mg/kg. Drug levels in serum were measured 
at 2 and 4 hours after dosing. The results are shown in Table 3*3»
Table 3»3 '■
Serum Levels of Oxamniquine in Rabbit following Intramuscular 
Administration of 4OQ mg/kg
Rabbit No. Sex Time of Sampling 
(Hours)
Serum Level 
(p.g/ml)
1 CT 2 N.D.
4 0.4
2 Cf 2 DNM
4 1 .1
3 9 2 DNM
4 1 .1
4 9 2 DNM
4 1 .1
ND = Not detected 
DNM ss Detected but not measurable
The same trend \iras seen in all four animals, i.e. serum 
levels were higher at 4 hours than at 2 hours, when in one instance, 
none at all could be detected, whilst in the three remaining animals 
the drug was present but at levels too low for accurate determination.
Serum Levels in Dogs
Two dosing regimens were used:
(a) Intramuscular injections at 100 mg/kg daily.
(b) Oral administration at 25 mg/kg twice daily.
Serum samples were taken 4 hours after the morning dose on day 0 
and day 25 from six animals in each group (three of each sex).
Oxamniquine could not be detected in the i.m. dosed animals, and was 
only just detectable (not measurable) at 4 hours on day 0 in half of 
the animals. On day 25 drug was just detectable in two animals alone.
Serum Levels in Mice
Oxamniquine was not detected in the serum of mice 4 hours after 
an oral dose of 750 mg/kg on the 24th day of a trial, in which the 
animals had been receiving 200 mg/kg/day in the diet.
Tritium Exchange in Vivo
Some tritium exchange occurred in vivo. Radioactivity was 
measured in mouse 48 hour post-dose urine samples and in samples 
collected between 48 and 96 hours. At 48 hours 10% of the excreted 
radioactivity was present as tritiated water, in the later samples this 
figure increased to an average of 17%.
Rabbit serum samples taken at 2 and 4 hours after intra­
muscular injection of radiolabelled drug showed progressive increases 
in tritiated water content. At 4 hours the serum level of radioactivity 
was equivalent to 3 2 .8 pg/ml measured prelyophilisation but only 2 3 -8 pg/ml 
after removal of tritiated water.
Blood Levels of Radioactivity
Whole blood radioactivity levels were determined after 
single oral doses of oxamniquine to six species. The results 
expressed as pg/ml of oxamniquine are given in Table. 3*4*
The levels of radioactivity determined on whole blood 
samples are not directly comparable with levels of oxamniquine which 
were measured in serum samples and in most instances the picture is 
further complicated by discrepant dose levels. Nevertheless, it is 
obvious that the levels of circulating unchanged drug are far lower 
than the total drug-related species in circulation indicating rapid 
metabolism. In one species, i.e. dog, whole blood radioactivity levels 
and serum levels of oxamniquine were determined after similar doses 
given by the same route. The peak blood radioactivity levels corresponded 
to an approximate serum level of ^12.0 pg/ml four hours after dosing 
(assuming radioactivity to be wholly extracellular) at which time 
levels of oxamniquine were below the limits of assay, i.e. < 0 .2 5 pg/ml. 
Identification of Metabolites
Urine samples were fractionated in exactly the same manner 
as described earlier (cf Chapter l) giving an extract of basic and 
neutral metabolites and two acid fractions.
Metabolite VII
Thin layer chromatography of the extract of bases and neutrals
; ' 
revealed variable amounts of unchanged oxamniquine in all species with
only small traces of other drug related compounds, none of which could be
identified. However, on one occasion an extract of mouse urine made at
pH 12.0 was examined after a massive oral dose of oxamniquine (750 mg/kg).
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Thin layer chromatography in ether-isopropylamine (19*1 v/v)
revealed a large amount of unchanged drug at Rf Oi 9 with a significant 
amount of a second yellow metabolite at Rf 0,5^ (metabolite VII).
Mass Spectroscopy
A mass spectrum was obtained (Fig. 3-1*)• The molecular
ion peak appeared at m/e 237 with a base peak at m/e 2 0 7.
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Fig. 3*1* Simplified mass spectrum of Metabolite VII
The absence of a fragment ion peak at m/e 72 indicated that the 
sidechain was no longer intact but as the compound appeared to be of 
odd mass the nitrogen atom was presumably retained. The most likely 
structure of the new metabolite was therefore (3 .1).
HOH C
(3.1)
A subsequent search for this material was later made in stored urine 
samples from orally dosed dogs and rabbits. The same metabolite was 
found in dog urine in trace amount (confirmed by M.S.) but was not 
detected in rabbit urine.
Acidic Metabolites
The acid metabolite V (see Fig. 2.16, p.59 ) excreted after 
administration of methamniquine was found to be the major urinary 
metabolite after oxamniquine administration in all of the species studied 
The other acid metabolite (IV) was also found in dogs, rabbits, hamsters 
and mice but was absent from the urine of rats and the one rhesus monkey 
dosed.
A third acidic metabolite was present in the urine of some 
species, the largest amount appearing in dog urine. This was believed 
to be a dicarboxylic acid (see Fig. 2.16 metabolite VI). A mass spectrum
of the metabolite after treatment with diazomethane showed a small 
pealc at m/e 280 with a much larger peak at rn/e 266 unrelated to it; 
suggesting that the spectrum was of a two component mixture consisting 
of di- and mono-methyl derivatives of VI (3 .2 ) and (3*3) •
H00CH COOC
COOCH
(3 .2) (3 .3)
Incomplete methylation of the 6-C00H group was expected as methylation 
of V with diazomethane also gave a very poor yield of the ester. 
Reduction of Oxamniquine
The metabolic studies carried out with methamniquine 
established the importance of the oxidative pathways of metabolism 
but little was learnt regarding the possible reduction of the nitro 
group apart from the fact that the primary amino compound resulting 
from complete reduction of the unchanged drug did not appear in the 
urine of orally dosed animals. In view of the known toxic potential 
of the metabolic intermediates of nitro group reduction in vivo it 
was considered important to examine the urines of oxamniquine dosed 
animals more closely for evidence of any amines which might be derived 
from either the drug or its metabolites.
Oxamniquine itself and the carboxylic acid V (see Fig. 2.16) 
are the major drug-related species in the urine of orally dosed animals. 
Numerous attempts to prepare either of their amino analogues by 
chemical reduction of the respective nitro compounds with titanous 
chloride, stannous chloride and lithium aluminium hydride have been 
unsuccessful. Catalytic hydrogenation was also tried without success.
As neither reduced compound was available for reference a 
specific search could not be easily undertaken and it was decided to 
estimate the amount of urinary arylamines excreted by dosed and undosed 
animals as a measure of nitro group reduction, by the use of the Bratton 
and Marshall diazo test. Urinary arylamine excretion has been 
monitored in rats following single oral doses of oxamniquine (200 mg/kg). 
Initial results analysed by Student t test show no significant differences 
in arylamine excretion between dosed rats (n = 7 ) and a group of undosed 
controls (n = 10). Work is currently in progress to supplement these 
data with results obtained in other species.
This initial result suggests that nitro reduction does not occur 
readily in vivo. This finding is consistent with Williams1 suggestions 
(1959) that readily excreted drugs are unlikely to underto extensive 
reduction as, a) oxamniquine itself is rapidly metabolised viz. serum 
levels of oxamniquine v. total ’drug related1 levels, and b) the major 
metabolite is a highly polar ampholyte.
Quantitative Determination of Urinary Metabolites
z-'
The urinary excretion of oxamniquine and two acid metabolites 
(IV and V) is shown in Table 3*5-
Table 3.5
Urinary Excretion of Oxamniquine, and Two Acid Metabolites 
in Six Species after Oral Administration of [^H] - Oxamniquine
% Urinary Radioactivity
.Species No Sex Dose
mg/kg
Oxamniquine Metabolite IV Metabolite V
Dog 2 9 60 1 6 .0 (1 2 .1 -1 9 .9 ) 1 0 . 6 ( 1 0 . 0 - 1 1 . 1 ) 4 4 . 5 (4 0 . 0 - 4 9 . 0 )
Rat 1 cr 60 27.0 Not detected * 45 .0
Hamster 2 ** cf 90 6 .6 3.1 5 6 .2
Mouse 9 4 00 3 8 .0 1 8 .0 33.8
Rhesus
monkey 1 9 95 2 .1 Not detected 6 9 .O
Rabbit 1 9 o o 16 .4 14.0 6 3 . I
* small amounts of Metabolite IV were found after relatively 
high doses, i.e. 200 mg/kg. ** Samples pooled.
Urinary Metabolites in Man
The urine of dosed volunteers contained only two obviously drug- 
related materials. One was unchanged oxamniquine present in small amounts 
and confirmed by mass spectroscopy, the other was metabolite V which was 
isolated as a crystalline solid and confirmed by methods previously 
described. Treatment of urine with 3-glucuronidase effected no change 
in the pattern of excreted metabolites. Chromatographic searches for 
glycine, glutamine and glutamic acid after acid hydrolysis (5M. acid for 
1 hour) of both neat urine,and of material eluted from the major 
metabolite band also proved negative. There is thus no evidence to 
suggest that metabolive V is conjugated to any extent with either glucuronic 
acid or the more common amino acids.
Schistosomicidal Activity of Metabolite IV
Metabolite IV was inactive against experimental infections 
in mice when administered orally at a dose level of 17 *5 mg/kg for 
four consecutive days*
CHAPTER FOUR
Investigation of a Species Difference in Metabolism: Further
Studies on the Metabolism of Methamniquine and Oxamniquine
in the Rat
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(a) Reference compounds.
(b) In vitro methodology*
(i) Preparation of liver fractions.
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(c) Assay of 6-methyl-7-nitro-l,2,3,4“ieirahydroquinoline 
2-carboxylic acid.
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(a) In vitro experiments.
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4. Discussion.
Introduction
Studies on the metabolism of methamniquine in six species 
revealed a major species difference in the fate of the compound.
The drug is extensively oxidised in vivo at the aromatic methyl group 
to a carboxylic acid metabolite (V) which is the major metabolite in 
all species, a reaction which involves an alcohol intermediate (II) 
(please refer to pull-out fig. 4 on page IO5 ). All species also oxidise 
the aliphatic sidechain in varying degree, to form a second carboxy 
metabolite (III) with the exception of the rat, in which species this 
metabolite was not found, although small amounts of the analogous acid 
(IV) were excreted when relatively high doses of oxamniquine (II) were 
given.
N-dealkylation of tertiary and secondary amines is a well-known 
microsomal reaction reviewed by McMahon (1966). The ease of removal of 
alkyl groups shows good inverse correlation with chain length for several 
differing amine types (La Du et al 1955, Smith et al 19&5, Abdel-Monem 
and Portoghese 1971), however, examples of N-deisopropylation are few. 
Removal of N-isopropyl groups has been reported by Smith et al (1965) 
in mice, by Vree and Van Rossum (1970) in man, and by Karim et al (1972) 
who found that disopyramide, an antiarrhythmic agent containing the 
N-diisopropyl group, was readily dealkylated in the dog but not in the 
rat. Klutch and Bordun (1967) also reported N-deisopropylation of 
N-isopropylmethoxamine in the dog but did not apparently observe this 
reaction in the rat although the summary of their paper is annoyingly 
ambiguous on this point.
It was thought, therefore, that the mechanism of sidechain 
oxidation would probably involve an initial N-dealkylation step to give 
a primary amine intermediate (VII) which would then undergo oxidative
deamination and further oxidation to give the acid end-product (ill). 
This proposed amine intermediate was never found in urine after dosing 
with methamniquine (I) but when oxamniquine (II) was dosed to mice and 
dogs, a minor metabolite was found in urine which was identified by mass 
spectroscopy as VIII. The subsequent finding that the acid III was 
present in the urine of a rat dosed with the amine VII (1 5 6 mg/kg) gave 
added weight to the proposed metabolic route and suggested that the 
failure of rats to oxidise methamniquine to the acid must be due to an 
inability to remove the isopropyl group from the alkylaminoalkyl side­
chain. This might be due to (a) an altered membrane conformation in 
the rat resulting in reduced substrate affinity or (b) the presence 
of an endogenous inhibitor in rat liver. An alternative but less likely 
explanation, for failure to detect III in rat urine could be its 
excretion in bile.
This chapter describes some experiments performed in a short 
incomplete investigation of the species difference outlined above. The 
results obtained are discussed and a possible mechanism is proposed.
Experimental
(a) Reference Compounds
Four compounds were prepared in addition to those whose source 
or method of synthesis has already been detailed.
6-Methyl-7-nitro-l,2,3 ,4~tetrahydroquinoline-2-carboxylic acid was 
synthesised by Dr. B. Kaye of the author's department. 6-Methyl- 
quinoline-2-carboxylic acid, prepared by a Reissert reaction on 
6-methylquinoline as described previously, was catalytically reduced 
on platinum oxide and nitrated to yield a red-orange solid which was
I
recrystallised from benzene, m.p. 136-138°. Found, C, 55*7, H,5-3,
N,11.5%; C H N 0 requires C,55.9, H,5-1, N,11.8/6. Mass spectrum:
11 122 Zf .
M+ 236, Infra red spectrum y (cm ^)l7l0 (>C=0).
Methyl-[6-methyl-7-nitro-1,2,3,4~tetrahydroquinoline]] -2-carboxylate. A solution
of 6-Methyl-7-nitro-l,2,3,4,“tetrahydroquinoline-2-carboxylic acid
(500mg) in methanol (100ml) was treated with an excess of a freshly
distilled solution of diazomethane in ether. The mixture was allowed
to stand at room temperature for 15 minutes and then evaporated to
dryness in vacuo at 40° after addition of a few drops of glacial acetic
acid to destroy the excess oi diazomethane. The solid obtained was
dissolved in ether (100ml), washed once, with an equal volume of M/100
NaOH and dried over anhydrous sodium sulphate. The ester was
recrystallised three times from methanol,yield l6 6.7mg, m.p. 134~136°.
Found, C,57-7, H,5 .5 , N,11.5, c12’Hi4’N2’°4 recluires ct 57.-6, H,5-6,
N, 11.2- Mass spectrum: M+ 250, Infra red spectrum: y (cm )^ 1725 
(>C=0 of ester grouping).
2-Hydroxymethyl-6-methyl-7-nitro-l, 2, 3, 4~tetrahydroquinoline was prepared 
by a selective reduction of the aforementioned ester with sodium 
borohydride. The ester (lg) was refluxed in methanol (200ml) with a
twenty-fold excess of NaBH (^3g) for four hours when reduction was
4
virtually complete judged by t.I.e.-Evaporation of the methanol followed 
by extraction with ethyl acetate from aqueous base yielded a yellow 
paste which was recrystallised twice from ethyl acetate/cyclohexane. 
Yield 230 mg, m.p. 100°. Found 0,59.3, H,6 .2, N,13.0%, C H N 0,
11 14 2 3
requires C,59-5, H,6.3, N,12.6%. Mass spectrum: M+ 222.
2-N-Isopropylaminomethyl-7~Nitro-lt 2,3,4,-tetrahydroquinoline. A 
solution of 2-N-isopropylaminomethyl-7-nitro-l,2,3,4,-tetrahydroquinoline 
6-carboxylic acid (132 mg) in M HC1 (70ral) was heated under reflux 
for one hour. After cooling in ice, M NaOH (130ml) was added and the 
mixture extracted twice with ethyl acetate (50ml). The extract was 
dried over anhydrous sodium sulphate, reduced to small volume (l-2ml) 
by rotary vacuum evaporation and the base then precipitated as the 
hydrogen maleate salt by trituration within a half-saturated solution 
of maleic acid in ethyl acetate. The yellow paste obtained after 
filtration was recrystallised twice from absolute ethanol. Yield,
50.4mg, m.p. 179°- Found, 0,55-8, H,6.6, N,11.5  C.._H N306 requires
0,55-9, H,6.3, N,11.5. Mass spectrum M+ 249-
b) In Vitro Methodology
i) Preparation of Liver Fractions
Two methods of preparation of liver subfractions were used.
The main point of difference was in the choice of homogenisation 
medium which was a sucrose solution when mitochondria were prepared and 
a potassium chloride solution for all other experiments when the mito­
chondrial pellet was not required. Both methods are described.
Method 1
Male rats, Wistar albino, 200-250g weight range and male 
white mice, 25~30g in weight were killed by cervical fracture and 
their livers removed immediately into a tared beaker of 0.32£4 ice-cold 
sucrose solution, weighed, and cut into small pieces with scissors.
They were then homogenised by hand in a Potter-Elvehjem type (1936) 
teflon-glass homogeniser by six up and down strokes. Cell debris and 
nuclei were removed by centrifugation at 700g for 10 rains. The 
supernatant was removed and re-centrifuged at 1 0 ,0 0 0 g.av. for 20 mins. 
in an M.S.E. High Speed 18 centrifuge. The supernatant was again 
removed taking great care not to disturb the mitochondrial pellet which 
was resuspended in 0 .25M. sucrose and washed twice by centrifugation at
24,000 g^av. for 10 mins. After the final wash the mitochondrial pellet 
was resuspended in the original volume of ice-cold O.25M sucrose.
Method 2
Male Wistar albino rats, 200-250g weight range, and a male 
rabbit (N.Z. White) weight 3-0 kg were killed by cervical fracture. The 
livers were removed immediately into ice-cold KC1 solution, 1.15% w/v, 
weighed,and homogenised in 4 volumes of KC1 using a power-driven teflon- 
glass homogeniser. The homogenate was centrifuged in polycarbonate 
tubes at 10,000 g.av. for 60 mins in an MSE Superspeed 50 centrifuge.
The -103,000 g supernatant (soluble fraction) was removed taking care 
not. to disturb the microsomal pellet, which was rinsed once with KC1 
before resuspending in the original volume of ice-cold KC1 using a 
small teflon pestle to aid resuspension.
(ii) Incubation Mixtures
Two incubation systems were used.
System 1 (used in studying the oxidative deamination of 2-aminomethyl- 
G-methyl-y-nitro-l,2,3 »4“tetrahydroquinoline)
NAD - 0,4 P-Moles
NADP 0.4 pMoles
Glucose-6-phosphate 20.0 pMoles
Nicotinamide 100.0 yMoles
Magnesium chloride 60.0 pMoles
Liver fraction (mitochondrial suspension —
or 10,000g supernatant - 500mg wet tissue) 2 .0  ml 
Tris buffer 0.1M pH 7.6 ml
Substrate (various amounts in tris buffer) 1.0 ml plus O.25M 
sucrose to final volume of 5.0 ml. Control incubates were included 
in each batch of tests containing all the listed reagents except for 
either liver tissue or substrate.
System 2
NADP 1.0 pMoles
Magnesium chloride 60.0  pMoles
Glucose-6-phosphate 2 0 .0  pMoles
Glucose-6-phosphate dehydrogenase
(Sigma) O .5  enzyme units
Substrates 2 .0  pMoles
Liver fraction (1 0 ,0 0 0 and 105,000g
supernatants or microsomes) 2 .O ml
Phosphate buffer 0 .1M pH 7.6 2 .O ml
Test mixtures and the usual controls were incubated for 30 minutes
in sealed tubes at 37° in a shaking water-bath after flushing with
oxygen for a few seconds. The reactions were stopped by addition of
M-NaOH (l.O ml) and extracted three times with equal volumes of ethyl
acetate. The mixtures were then acidified with M-HC1 (2.0 ml) and
extracted with n-butanol.
c) Assay of 6-Methyl-7-nitro-l,2,3,4~tetrahydroquinoline-2-
carboxylic acid (III)
Metabolite III was assayed in extracts of liver incubations 
as its methyl ester by a gas-liquid chromatographic method. The 
instrument used was a Varian 1200 (Varian Associates, Walton-on- 
Thames, Surrey) fitted with a flame ionisation detector. The column 
was of glass, 5 ’ in length x l/8M external diamter and packed with 
Gas-chrome Q, 100-120 mesh coated with 0V-17, a phenylmethylsilicone 
(5% v/w) as the stationary phase. The operating temperatures were: 
Injection port 230°, column oven 230°, detector 250°. The carrier 
gas was nitrogen (whitespot) at a flow rate of 25 ml/min.
Column Calibration
Stock solutions of both alkanes and the compound to be 
assayed were prepared in chloroform solution. 6-Methyl-7~nitro-l,2, 
3,4-tetrahydroquinoline-2-carboxylic acid ester 5 9 *6 pg/ml 
Hexacosane 45.7 p.g/ml
Octacosane 43*3 P-g/ml
Two series of mixtures of compounds and alkane standard were prepared 
to cover a suitable range of weight ratios by taking fixed 1 .0  ml 
amounts of the respective alkanes plus varying amounts of the standard 
ester solution. Grade A glassware was used throughout in making these 
dilutions.
Table 4 .1
Composition of Ester/Alkane Mixtures and Weight Ratios
Standard Ester Alkane (C o r  C^)
Weight Ratios
E s te r /C 26 Ester/^g
(mis) (mis)
1.5 1.0 1.96 2 .0 6
1.2 1.0 1.56 1 .6 5
1 .0 1 .0 1.30 1 .3 8
0 .8 1 .0 1 .0 4 1 .1 0
0 .6 1 .0 0 .7 8 O .8 3
0 .4 1 .0 O .5 2 0.55
Sample injections from each mixture were chromatographed and
the peak heights measured. Standard curves were constructed by 
plotting the observed peak height ratios against the known weight 
ratios and used for determining the amounts of ester present in test 
samples.
Quantitation of Derivaiisation
A stock solution of 6-methyl-7-nitro-l, 2,3* 4~‘t©'trahydro- 
quinoline-2-carboxylic acid (ill) was prepared in chloroform at a 
concentration of 1^.00 p,g/ml. Aliquots in duplicate of this solution 
were taken, 0 ,2 5 ml and 0 ,1 5 ml equivalent to 100 p,g and 60 pg 
respectively of the acid and treated with 1 ,0  ml of a freshly distilled 
ethereal solution of diazomethane (i.e, a large excess). After 5 minutes 
at room temperature the mixtures were rotary, evaporated in vacuo and
1.0 ml volumes of the alkane stock solutions added. The amount of ester 
present was then determined by g.l.c. assay.
Assay of 2-carboxylic acid in Liver Incubates
At the end of the incubation period the reactions were 
stopped by the addition of 11 NaOH (0.5 ml) and extracted once with 
an equal volume of ether to remove the unreacted starter substrate.
The carboxylic acid was removed by addition of 11 HC1 1.0 ml followed 
by two extractions with an equal volume of ethyl acetate. After 
drying over anhydrous sodium sulphate the extract was evaporated to 
dryness and treated with an excess of diazomethane in ether (l.O ml).
The mixture was allowed to stand at room temperature for 5 minutes 
after which the excess diazomethane was removed by rotary evaporation 
in vacuo and the extract redissolved in chloroform containing the 
internal standard (C  ^or ^2 8 *^
d) Isolation of Biliary Metabolites
Biliary Cannulation of Rats
Male Wistar albino rats, 330-3509 body-weight, were 
anaesthetized with urethane, each animal receiving 0 .7  ml of a 25% 
aqueous solution per 100g bodyweight by subcutaneous injection.
Their bile-ducts were cannulated with polythene tubing (PP25 Portland 
Plastics) as described by Abou-El-Uakarem et al (1967a) and the cannulae 
led out through the abdominal wall via an aspiration needle at a site 
some distance removed from the main incision line. This needle was 
re-inserted through the abdomen into the peritoneal cavity before 
suturing the animal to facilitate introduction of drug and to obviate 
the risk of (a) possible perforation of the ileum or (b) subcutaneous 
injection.
As the drug was well tolerated after oral doses of 250 mg/kg, 
three rats were given intraperitoneal doses of C^H] - methamniquine 
maleate ( = 2 00 mg/kg free base) after cannulation of their bile ducts.
This dose level proved to be acutely toxic all three animals dying 
within 3O-4 5 mins. A second batch of three rats were then dosed.
It was intended to give each animal a dose of 30 mg/kg (2 ml of an 
injectable solution) but unfortunately the first animal was given 3 mi 
in error, i.e. a dose of 45 mg/kg, leaving insufficient material to 
dose the remaining two rats at the same dose level. These rats were 
therefore given doses of 30 mg/kg and 15 mg/kg respectively. Bile was 
collected for seven hours at which time the animals were sacrificed. 
Chromatography of Bile
Aliquots of each bile sample (20 pi) were chromatographed for 
a distance of 10 cm. on silica gel thin layers developed in three 
different solvents. .
A Propan-l-ol-aq ammonia sp. gr. 0.88 (7:3 v/v)
B Butan-l-ol-aq ammonia sp. gr. 0.88 (1:1 v/v upper phase)
C Butan-l-ol-acetic acid-water (60:15:25 by vol)
Quantitative Determination of Radioactivity 
Bands of silica (0 .5  mm) were removed by careful scraping , 
transferred to counting vials and crushed to a fine powder with a 
spatula end. Distilled water (l.O ml) was added to each vial, they 
were then allowed to stand for a minimum of 60 minutes with gentle 
agitation from time to time, after which 10 ml of NE 25O (commercially 
available dioxan based scintillator) were added and the samples assayed 
for radioactivity by liquid scintillation spectrometry. This method
was shown to give quantitative elution of radioactivity, i.e. solution
\
counting efficiency, thus overcoming the problems of self-absorption 
attendant to the counting of tritium-labelled silica samples.
Enzyme Hydrolysis
Aliquots of each bile sample (100 plitre) were incubated 
overnight at 37° with ’Ivetodase ’ solution (100 p,l) containing 5^0 
Fishman units of (3-glucuronidase and free from sulfatase activity. 
Following incubation, samples (4 0 plitres) were removed from each test 
mixture and chromatographed as described previously.
Isolation of a Biliary Aglycon
The amount of material available from individual bile samples 
was insufficient to allow for identification of the aglycons. 
Consequently,. the samples were pooled and treated with (3-glucuronidase 
to obtain the maximum possible yield. As hydrolysis with 'Ketodase' 
appeared to be incomplete (vide infra) the enzyme preparation used in 
this experiment was one of higher potency, a crude extract of Helix 
pomatia containing 100,000 Fishman units (Sigma), and bile was buffered 
with 0.1M acetate buffer pH 5»0.
Following incubation, the pH was adjusted with 11 NaOH and the 
mixture extracted twice with ethyl acetate. The extract was chromato­
graphed on silica gel in a solvent system consisting of benzene-ethanol- 
aq ammonia (7 0:3 0il by vol) when the major band (yellow) was seen to run 
close to the front and similar in Rf to a methamniquine marker spot.
This band was scraped, eluted with methanol and re-chromatographed in 
silica gel developed in ether. In this system methamniquine was barely 
moved from the origin, whereas the unidentified metabolite again moved 
close to the front, and was very well resolved from numerous bands of 
non-drug-related materials visible under ultra-violet light (2 5 4  
366  nm).
RESULTS
Assay of 6-Me.thyl-7~Nitro-l,2,3t4~Tetrahydroquinoline-2-
Carboxylic Acid (ill)
Quantitation of Derivatisation
The efficiency of methylation of III was determined by g. I.e. 
assay of the ester formed using both and C^g as reference internal 
standards, Methylation was essentially quantitative and similar 
efficiencies were obtained using either standard as the results in 
Table 4*2 indicate*
Table 4*2
The Efficiency of Methylation of the Carboxylic Acid (III) 
Determined by glc using Alternative Internal Standards
Weight of acid
p-g
Theoretical yield 
of ester p<g '
Ester (p.g) by glc Efficiency %
026 028 026 028
100 IO5 .9 1 0 6 .9 . 103.9 1 0 0 .9 9 8 .1
60 6 3 .6 6 1 ,9 6 2 .8 97.4 9 8.7
Deamination of 2-aminomethyl-6-methyl-7-nitro-l,2,3,4-tetrahydroquinoline 
(VII) in vitro by whole liver homogenates 
The primary aliphatic amine analogue of methamniquine (VII) was 
incubated with whole liver homogenates of rat and mouse liver using 
system 1. Deamination occurred with both rat and mouse liver to give 
the carboxylic acid (ill) which was detected chromatographically. No 
attempt was made to determine these conversions quantitatively.
Cellular Location of Enzymatic Activity Catalysing the Deamination of VII 
Deamination of VII was studied using 10,000g supernatants and 
mitochondrial suspensions prepared from the livers of rats and mice.
Table 4-3 shows the amount of acid end-product formed 
measured as the methyl ester derivative. The mean recovery of the acid 
(ill) from spiked (100 p,g) control incubations was 80%. A correction 
factor (xl.2 5) was therefore applied to the test data.
Table 4 .3
Comparative Deaminative Activity of Rat and Mouse Liver Fractions 
towards 2-aminomethyl-6-methyl-7-nitro-l,2,3* 4~tetrahydroquinoline
Liver subfraction Acid formed jxMoles g  ^h. ^
Rat Mouse
10,000g 
supernatant 0 .0 9 0 .0 4
Mitochondria -1.76 1 .4 6
It is important to note here that when tissues were prepared
\
by homogenisation in 1.15% w/V KC1 using a power-driven pestle 
considerable deaminative activity was present in the post-mitochondrial 
supernatant presumably due to contamination by solubilised mitochondrial 
enzymes.
Metabolism of Methamniquine and Oxamniquine in Vitro
When methamniquine was incubated in vitro with rabbit and rat 
liver subfractions (l0,000g and 105,000g supernatants and microsomes) 
and. added .co-factors, substantial conversion to II occurred in both
“95“
10,000g and microsomal fractions but no N-dealkylated product (VII) 
could be detected chromatograph!cally. This was not surprising as 
when the primary amine itself was taken as substrate it was found to 
be extensively metabolised by both the 10,000g supernatant and the 
microsomal fraction. Chromatographic examination of acid extracts of 
test incubations containing methamniquine and the 1 0,000g fractions 
of rabbit and rat liver showed that the acid metabolite III had been 
formed by rabbit liver but not by rat liver. Under normal circumstances 
the evidence would have been confirmed by g.l.c. and by mass spectroscopy 
but this work was carried out in the Biochemistry Department at the 
University of Surrey where time did not permit more than t.l.c. comparisons 
with authentic material.
Assuming that III had been formed from I by rabbit liver, 
failure to detect the proposed intermediate VII allows for two possible 
conclusions, either its half-life is too short to allow detection or 
that III was produced by a different route not involving a primary 
amine intermediate.
In the case of rat where no acid end-product was formed it 
is still not possible to state with certainty that the dealkylation 
does not occur invoking the first reason that was suggested in the 
case of the rabbit. In this context the rabbit may have been a poor 
choice of species for comparison as the evidence for primary amine 
formation in vivo was obtained in dogs and mice.
It might be argued that if hydroxylation of the methyl group 
in rat liver is competitively inhibiting N-dealkylation when 
methamniquine (I) is the substrate, then by-passing this reaction by 
taking oxamniquine (II) as substrate should lead to dealkylation.
A small amount of the expected amine metabolite (VIII) was available as
an authentic reference marker to assist in identification, but when 
oxamniquine was incubated with rat liver microsomes, this metabolite 
was not found. Some metabolism did occur but whether this involved 
further metabolism of the elusive amine or an attack at some other 
site on the substrate molecule was not certain.
Metabolism of ’Desmethyl1 Methamniquine in Vitro
As a small quantity of the acid (V) was available it was 
decided to decarboxylate it to obtain the ’desmethyl1 analogue of 
methamniquine (4*l) to simplify the problem of studying N-dealkylation, 
by removal of the competing site of oxidation.
This compound was used as a substrate in vitro only with 
rabbit liver and only on one occasion when it was metabolised by the 
10,000g supernatant to an acid metabolite with a similar Rf value to 
III and which .was presumed to be (4 *2) as removal of the methyl group 
would probably have little influence on its t.l.c. mobility.
A metabolite was also seen in the base extract, after 
incubation with the microsomal fraction,which had a similar Rf value 
to authentic VII and which could have been its desmethyl analogue, (4*3)* 
Biliary Excretion
The biliary excretion of radioactivity after intraperitoneal
O
injection of t H]-methamniquine to three rats is shown in Table 4 .4 .
' ' ' ' - • \ \
Table 4*4
Biliary Excretion of Radioactivity in Three Rats after Intra-
3
peritoneal Injection of [ H]-Methamniquine
Rat Dose Collection 
period (hours)
Recovery
mg/kg p,Ci )iCi % of Dose
1 45 38.46 6* 1.45 3*77
2 30 25.64 7 3*78 14*74
3 15 1 2 .8 2 7 3*66 2 8 .5 4
* Rat died at this time
Metabolite Identification
Thin layer chromatography of bile samples indicated that at 
least three, and possibly four, metabolites were excreted in each case, 
the distribution of radioactivity on chromatograms being essentially the 
same in respect of any particular solvent (see example fig. 4-la)*
After (3-glucuronidase treatment there was a distinct change in the 
radioactivity distribution pattern (see fig. 4*lb)» a peak of radio­
activity at Rf 0.45 (Solvent A) became smaller at the expense of a small 
peak near the solvent front which was greatly increased. A peak at 
Rf. 0.70 which corresponded to an authentic 6-carboxy reference marker
spot remained unchanged after enzyme treatment. This picture was similar 
when the samples were chromatographed in other solvents, except that in 
an acidic solvent (C) it was obvious that the enzyme treatment had 
released more than one aglycon. The acid metabolite (ill) was not 
detected in the bile.
Mass Spectroscopy
The major aglycon was isolated as described earlier and a mass 
spectrum obtained (fig. 4 -2 ). '
The molecular ion peak occurred at m/e 222 and being of even 
mass indicated that the compound now had an even number of nitrogen atoms 
The base peak of the spectrum was at m/e 191 (M-3l)i a metastable peak 
confirming its relationship to the molecular ion. Subsequent loss of 
46 from the 191 fragment confirmed by a metastable ion indicated the 
presence of the nitro group. Loss of a nitrogen atom therefore indicated 
some modification of the sidechain which was strengthened by the absence 
of the characteristic peak at m/e 72 (CH =j?JH-CH(CH ) ). It was thus
u  j) cL
clear that the loss of 31 from the molecular ion must be loss of the new
sidechain which could sensibly be only— CH OH and indicating a structure
» d*
for the metabolite as shown below (4 -3)-
C
3
N
2 H
(4 -3 )
The structure was subsequently confirmed by an unambiguous 
synthesis of 2-hydroxymethyl-6-methyl-7’*nitro-l, 2,3» 4“^e't*'ahydroquinoline 
which was chromatographically identical to the biliary metabolite in 
three solvents.
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4.1. Distribution of radioactivity on silica gel thin 
layer chromatograms of rat bile (a) before and
(b) after treatment with p-glucuronidase.
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Fig. 4*2. Simplified mass spectrum of rat biliary aglycon.
Quantitative Determination of Biliary Metabolites
The results of quantitative determinations of the 6-carboxy 
metabolite (V) and the alcohol (IX) (see Fig. 4 .3) are given in
Table 4 .5 .
It is interesting to note that the relative amount of IX 
excreted increases as the dose level is increased* This suggests 
that sidechain oxidation is a route of secondary importance in the 
rat.
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Table 4*5
Quantitative Determinations of Rat Biliary Metabolites
O
following Intraperitoneal doses of [ H] - Methamniquine
Rat Dose
mg/kg
% Total Biliary Radioactivity
V IX
Other
metabolites
1 45 18 31 51
2 30 24 19 57
3 32 14 54
Discussion
The extensive metabolism of the primary amine (VII) by rat liver 
microsomes made it impossible to study satisfactorily the N-dealkylation 
of methamniquine (i). As conversion of (I) to (ill) occurred with the 
10,000g supernatant of rabbit liver but not with a similar preparation of 
rat liver and as the amine (VII) was shown to be converted to the acid 
(III) by rat liver 10,OOOg supernatant it seemed probable that N-dealky­
lation did not occur in rat liver. However, the subsequent identification 
of an alcoholic metabolite (IX) in rat bile after administration of 
methamniquine suggests that such a conclusion may well be wrong as the 
alcohol could have been produced in vitro and escaped recognition as its 
t.l.c. mobility differs only slightly from methamniquine in the systems 
that were used.
More recent work has shown that an analogous metabolite (X) is 
excreted as a glucuronide in the bile of rats after dosing with oxamniquine 
(II). Only trace amounts of this metabolite were found in rat urine and 
it has so far not been found in the urine of other species. Biliary 
excretion studies in other species are required now to determine whether 
this metabolite is peculiar to the rat.
Excretion of the alcohol (IX) by rats thus provides a ready 
explanation of the species difference in respect of acid (ill) excretion.
As both alcohol and acid sensibly stem from a common aldehyde intermediate 
it is interesting to speculate on its genesis in vivo and to seek possible 
explanations for its different fate in the rat.
The proposed aldehyde could be formed by two alternative routes. 
One route (shown by solid arrows in Fig. 4*3) requiring an initial 
dealkylation step followed by oxidative deamination, the other (broken
arrow in figure) through oxidation of the alpha carbon atom adjacent to 
the ring to form an unstable carbinolamine which would then lose isopropyl 
amine to form the aldehyde directly. Such a mechanism was proposed by 
Brodie et al (1958) to explain the formation of phenylacetone from 
amphetamine by rabbit liver microsomes and was confirmed by Parli et al 
(1971) by oxygen-18 studies.
The experimental evidence suggests that the first mechanism 
occurs in those species which metabolise the sidechain to an acid end- 
product, the aldehyde being formed in the mitochondria, as opposed to the 
rat in which species the aldehyde is probably generated microsomally by 
the second mechanism. ■ . .?
The primary amine (VII) has never been detected in the urine 
of animals dosed with methamniquine (i) but when oxamniquine was dosed 
to mice and dogs the amine (VIII) was present in addition to the acid (IV) 
confirming that N-dealkylation had occurred in these species. Although 
trace amounts of (IV) were also found in rat urine the amine (VIII) was 
not detected suggesting that dealkylation occurred minimally, if at all. 
The amine (VII) was subsequently dosed to rats when large amounts of the 
acid (III) appeared in the urine providing further evidence that sidechain 
dealkylation of (I) and (II) cannot be a significant route of metabolism 
in rats.
Whereas both rat and mouse liver mitochondria actively deaminated 
(VII) in vitro, the 10,000g supernatants were both inactive in this 
respect. This was an important finding implying that any primary amine 
produced by microsomal dealkylation in vivo would have to penetrate the 
mitochondria for deamination to occur. Thus the proposed aldehyde would 
be generated in the mitochondria where it would probably be rapidly
oxidised to the acid and not be exposed to the oxido-reductases of the 
soluble fraction.
In the rat the principal end-product of sidechain metabolism is 
an alcohol rather than an acid. It is suggested that this alcohol is 
produced by an oxido-reductase in the cell sap favouring reduction of an 
aldehyde produced in the microsomes. The intracellular site of formation 
of the aldehyde is therefore the significant factor in determining its 
subsequent fate. There is no positive evidence that deamination of (I) 
and (II) does occur microsomally in the rat or other species and clearly 
this is a point worthy of further investigation.
Two recently published results are of some interest in connection 
with this investigation. Sullivan et al (1971) found that N-cyclopropyl-
2-chlorophenoxyethylamine was metabolised in rats to both 2-chlorophenoxy- 
acetic acid and 2-chlorophenoxyethanol. They concluded that deamination 
was probably a microsomal reaction as 2-chlorophenoxyethylamine was found 
to be a poor substrate for rat liver mitochondrial enzymes. Nicholson 
(1971) found 1,2-dihydroxy-1-phenylpropane glucuronide in the urine of 
ponies after administration of ephedrine. He proposed a ketone precursor 
of the alcoholic metabolite and demonstrated appreciable amounts of the 
alcohol in urine after administration of the ketone. This observation 
lends weight to the argument for the involvement of an aldehyde precursor 
of the alcohols excreted in rat bile after administration of methamniquine 
and oxamniquine as it is unlikely that they could be formed in a one-step 
reaction.
- JUJp-
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INTRODUCTION
In the last decade the mortality from tuberculosis has fallen 
in almost every country. Increased living standards and better anti­
tuberculosis services, particularly in the better developed countries, 
have brought about a rapid reduction in the number of infectious cases 
and in some countries there are good prospects of eradicating the disease 
entirely within the next few years (Heaf 1968). Clinical experience 
has shown that the most effective and least toxic drugs are (a) isonicot- 
inic acid hydrazide (INH); (b) para-aminosali^cy^lic acid (PAS);
(c) streptomycin, an antibiotic elaborated by Streptomyces griseus and
(d) thiacetazone. Used in various combinations of two or three they 
constitute the best therapy currently available and can be highly 
effective (Bignall 1 9 68).
Despite these successes, tuberculosis remains a major world 
health problem leaving no room for complacency. Optimal therapy is 
lengthy, requiring long-continued co-operation between patient and 
doctor and where regimens are not strictly applied there is a grave danger 
of drug resistance developing. Although the tubercle bacillus is 
sensitive to an increasing number of antibiotic and chemotherapeutic 
agents, there are few which do not display undesirable toxic side effects 
and-few which are cheap enough for mass usage in under-developed countries 
where the emergence of resistant strains is posing an increasing problem.
In searching for a new inexpensive tuberculostatic drug, a 
number of substituted indazoles were synthesized and tested both in vitro 
•and against experimental infections in mice. The most promising of 
these was dinitroindazole.
It has a protective activity when dosed to newly infected mice 
i.e. the mean survival time of test groups is considerably greater than
for undosed control groups, but its in vitro activity is low, the 
minimum inhibitory concentration (M.I.C.) against Myco tuberculosis 
strain II37 Rv being 12.5 VLs/m *^ These observations suggested that the 
drug may be metabolised to a more active species in vivo.
This chapter is an account of a short study aimed principally 
at determination of the mode of metabolism in mice and discovery of the 
active metabolite(s) if such exists.
EXPERIMENTAL
REFERENCE COMPOUNDS 
3[ H]-Dinitroindazole. 5**Witroindazole (Aldrich Chemical Co. Ltd., 
Milwaukee, Wisconsin, U.S.A.) was randomly tritiated by the Wilzbach (1957) 
catalytic exchange process at the Radiochemical Centre, Amersham. The 
synthesis was completed by nitration of the tritiated material, yielding 
dinitroindazole which was purified by re-crystallisation from ethanol.
The final product had a radiochemical purity of 98*7% and a specific 
activity of 13*89 p-Ci/mg. Labile tritium having been exchanged, the 
location of the label was assumed to be as indicated (5 *i)*
NO
(5*1)
!
3-Hydroxy-5^ 7~dinitroindazole. An analytically pure sample was 
received from Dr. J.D. Hardstone of Chemical Research Department,
Pfizer Ltd. It was synthesised according to the method of Kenner 
(1914) by mixing an alcoholic solution of hydrazine hydrate with a 
solution of methyl 2-chloro-3,5“dinitrobenzoate in warm alcohol. 
l-Methyl-5,7-dinitroindazole. An analytically pure sample was obtained 
from the source quoted above. The compound was synthesized by methyl­
ation of dinitroindazole with methyl iodide and the isomers resolved 
by column chromatography on silica gel.
5-Nitro-7-aminoindazole was produced from dinitroindazole by micro­
biological reduction. Dinitroindazole (500mg) was added to 500ml of 
an actively growing nutrient broth (Oxoid C.M.67) culture of rat faecal
micro-organisms. The culture was incubated in a screw-capped bottle
o
under microaerophilic conditions m  a shaking water-bath at 37 for 24 
hours. The culture was then filtered through a Seitz pad, made basic 
with 2M-NaOH to pH 12.0 and twice extracted with an equal volume of 
ethyl, acetate. The extract which was a bright lemon yellow in colour 
was washed once with M/lOO HC1, dried over anhydrous sodium sulphate 
and reduced to a volume of l-2ml by rotary evaporation in vacuo. The 
total extract was applied to a column of Sephadex LH 20 gel in methanol 
(40 cm x 3 cm) and eluted with methanol. The major component of this 
fraction was a well defined orange band which increased in width due to 
diffusion as it passed down the column. This band was collected, 
evaporated to 0.5ml and applied to a second column of LH 20 Sephadex 
in methanol (20 cm x 2 cm). The discrete band eluted with methanol 
appeared to be pure by thin layer chromatography on silica gel in three 
solvent systems and was readily crystallised from benzene. Final yield
after two recrystallisations 9 6 .2 mg, m.p. 230-232° (uncorrected)
Found: C, 4 7.4, H, 3 .4, N, 3 1.2 , requires C, 4 7*2, H, 3 .4 ,
N, 31*4%* Details of the identification and proof of structure of 
this material appear later in this chapter.
5-Nitro-7-glucuronosylaminoindazole was prepared by a modification of 
the method of Ishidate et al (1959)*
5-Nitro-7-aminoindazole (10 mg) was dissolved in a few drops of dry 
acetone. A stoichiometric amount of sodium glucuronate (Sigma Chemical 
Co.) was taken and dissolved in two or three drops of distilled water. 
Drug and glucuronate were then mixed together and two drops of glacial 
acetic acid added. The mixture was allowred to stand overnight at 4° 
when a small amount of crystalline solid was obtained. This was washed 
three times with 2 ml volumes of wet ether and after addition of 2 drops 
of NaOH a further final washing with ether was carried out. Visual 
inspection of a thin layer chromatogram of the product on silica gel 
developed in solvent E showed two yellow spots. A small one which ran 
close to the solvent front corresponded to unreacted starter material, 
whilst the second, a much larger spot was located a short distance from 
the origin. This slow running material gave a positive slate blue colour 
when sprayed with the naphthoresorcinol spray for glucuronides described 
by Bridges, Kibby and Williams (1965)* On spraying with the cinnamalde- 
hyde reagent both spots gave a deep purple colour; the free arylamine 
reacting immediately, in sharp contrast to the second material which 
needed several minutes for full colour development. This slow colour
development was taken as evidence for the attachment of the glucuronyl
7 1
moiety at N , attachment at N being precluded. The synthesized
conjugate could not be isolated in a pure state, it was considered
however to be satisfactory for chromatographic purposes.
5~Nitro-7~sulphaminoindazole, Chlorosulphonic acid (0.1 ml) was added 
to dry pyridine (0 . 5 ml) previously cooled in an ice bucket. 
5-Nitro-7-aminoindazole (10 mg) in pyridine (0.3 ml) was then added and 
the white solid which formed on the wall of the test-tube was scraped 
down into the pyridine-drug mixture. A^ter standing overnight at Zj.° the 
mixture was made basic with a little M NaOH and washed four time^ with 
5 ml volumes of ether to remove pyridine and any unreacted starter 
material. The aqueous phase was reduced in volume and chromatographed 
on silica gel developed in solvent E. Two yellow spots were seen, one 
small and fast-running, the other a larger spot of much slower mobility. 
On spraying with the cinnamaldehyde reagent this spot slowly developed 
a deep purple colour, IO-I5 minutes being required for full colour 
development. This slow colour development was consistent with the 
findings of Boyland, Manson and Orr (1957) that^ arylsulphamates are 
hydrolysed in cold acid solution to yield free arylamines. This material 
was used for chromatographic purposes without further purification, 
l-Methyl-5-nitro-7-aminoindazole was produced from 1-methyl-dinitro- 
indazole (5OO mg) by microbiological reduction using the method described 
for the reduction of dinitroindazole. At the end of the incubation 
period the Culture was extracted twice with ethyl acetate without prior 
pH adjustment. Chromatography on a column of Sephadex LH20 gel in 
methanol (4O x 3 cm) enabled two major orange-yellow bands to be 
separated from starter material. Further chromatography of the slower 
of these bands on a second column of Sephadex LH20 in acetone (20 x 2 era) 
gave an orange material which was recrystallised once from chloroform 
followed by recrystallisation from methanol. Final yield after drying 
59*3 mo Had m.p. 232° (uncorrected). Found: C, 49*7, H, 4*2, N, 29*0%,
C0HQN 0 requires C, 50*°i H, 4 *2, N, 29.2%.
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l~Methyl-5~aniino-7~nitroindazole. The second orange metabolite obtained 
from microbial reduction of 1-methyl-dinitroindazole was purified by thin 
layer chromatography on silica gel developed in solvent D after attempts 
to purify it by column chromatography on Sephadex LI120 and on silica gel 
using a variety of eluting solvents had proved abortive. It could not 
be crystallised and appeared to be readily oxidised at relatively low 
temperatures to red coloured compounds. It gave a deep purple colour 
when sprayed with the cinnamaldehyde reagent as did the first metabolite. 
Unlike that material it was readily diazotised and coupled in the Bratton 
and Marshall reaction (1939)- Details of identification of this 
metabolite appear later in the results section,
(A solution of this metabolite in acetone was stored at 4° £°r 
several weeks when a few clusters of deep orange-brown needle-like 
crystals formed. These clusters were carefully removed with a seeker 
and drained of solvent. They were then dried in a vacuum oven at room 
temperature for seventy-two hours. The compound melted sharply at 170° 
(uncorrected). Found: C, 50*8, H, 4 .4 , N, 28.5, ^8^8^4^2 : ^3^6^
requires C, 5 0.4, II, 4 .4, N, 2 8.3 .
ANIMALS
Male white mice (Charles River C.D. strain), 25-359 weight 
range, were used in all mouse experiments with the exception of the 
neomycin pretreatment experiment when University of Surrey, strain A2G 
mice were employed. Rats used were male Wistar albino (Charles River) \ 
200-300g.
O
t HU - Dinitroindazole suitably diluted with unlabelled drug 
was administered orally to mice and rats by stomach tube, the compound 
formulated as a suspension in either (a) 25% (v/v) Cremophor-El in 
physiological saline (0 .85% w/v), or (b) c o m  oil. For intraperitoneal
injection the compound was dissolved in 2 ml of polyethylene glycol 
300 (PEG 300).
The insolubility of the drug made administration of accurately 
determined doses difficult. In all cases where suspensions were used, 
an extra 10% above the calculated dose was allowed to offset wastage, 
and the contents of the mixing vial and syringe after administration 
were carefully washed out with methanol and radiochemically assayed in 
order to determine the true dose.
Mice and rats were housed in glass 'Metabowls1 (Jencons) for 
the duration of experiments with free access to food and water.
Urine samples were collected at 24 hour intervals. No preservatives 
were added routinely to the urine receivers but in some later experiments 
a few mis of saturated sodium bicarbonate were added prior to collection 
to stabilise acid-labile metabolites.
Mice and rats were maintained 011 Spiller-Spratt's small animal
diet.
Neomycin Pretreatment
A batch of three male mice were given a seven day course of 
neomycin sulphate 100 mg/kg prior to an oral dose of dinitroindazole.
The antibiotic was administered by stomach tube, each animal receiving 
daily 0.5 ml of a 6 mg/ml solution in distilled water.
Details of all radioactive doses administered during the study 
are summarised in Table 5*1*
Table 5-1
'Species No. of 
Animals
Dose
mg/kg
Route Specific Activity 
p-Ci/mg
Total Activity 
p,Ci
Mouse 4 115 p.o 9.34 10 5 .92
Mouse 4 130 p.o 2 . 0 0 2 2 . 4 6
Mouse 4 155 p.o 9 . 8 8 210.99
Mouse 3 85 p.o 2 . 5 6 27.41
Mouse 3 140 p.o 2 . 6 5 47.12
Mouse 3 140 p.o 6.93 7 5 .8 6
Mouse 3 55 i-P 1 3 .8 9 5 3 . 8 4
Mouse 8 150 p.o 11.5 3 4 8 .7 3
Rat 1 190 p.o 3 . 1 0 1 1 6 .9 0
Rat 1 165 p.o 4 . 8 0 231.94
ISOLATION AND IDENTIFICATION OF METABOLITES 
Extraction Procedures
Two schemes of urine fractionation by solvent extraction were 
used (Fig. 5.1).
The organic phase moves always to the left in the flow diagram 
and is depicted by an unbroken line.
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Fig. 5»1* Scheme for urine fractionation by solvent extractions.
Scheme II
A series of buffer solutions of integral pH values were 
prepared ranging from pH 1.0 to pH 8.0. Two buffer systems were used 
to obtain this series.
1. Sorensen’s glycine 
(pH 1.0 —  pH 2.0)
Citrate-phosphate 
(pH 3.0 —  pH 8.0)
Solution A. 0.1M glycine + 0.1M NaCl
Solution B. 0.1M HC1
Solution A. 0.2M NaoHP0 
—  2 4
Solution B. O.lli Citric Acid 
Compositions of buffer mixtures were obtained from Documenta 
Geigy Scientific Tables (1956). One ml volumes of urine were mixed with
3 . 0  ml of each buffer solution in stoppered tubes. After standing at 
room temperature for 10 minutes each tube was extracted twice with an 
equal volume of ethyl acetate using a whirlimixer. The phases were 
separated by centrifugation at 1 , 5 0 0 rpm for 10 minutes and the organic 
phase carefully removed. The extracted radioactivity was determined by 
liquid scintillation counting of aliquots removed from known volumes. 
Enzyme Hydrolysis
\
Two ml of pooled mouse urine was diluted with three volumes 
of Mcllvaine’s buffer pH 7.0. The diluted urine was divided into two 
equal portions. To one was added 2,000 Fishman units of (3-glucuronidase 
obtained from Esch. coli (Sigma Chem. Co. Type V-A); the second tube 
served as a negative control. A third tube containing phenolphthalein 
glucuronide (Sigma) plus enzyme was set up as a positive control. All 
tubes were incubated at 37° for 18 hours.
Following incubation test and control urines were extracted 
twice with an equal volume of ethyl acetate. The pH of the urine 
samples was then adjusted to 1*0 with M_ HC1, and after standing for 
10 minutes at room temperature two further extractions with ethyl acetate 
were carried out.
CHROMATOGRAPHY 
Thin-Layer Chromatography
Separations of metabolites and comparison of Rf values with
authentic markers were carried out on commercially prepared plates of
silica gel F , layer thickness 0.25 iron (E. Merck, Darmstadt Germany)
254
and on polyamide plates of a similar thickness prepared with polyamide 
powder (E. Merck) 5^9 slurried in methanol (llOml).
Developing solvents employed were:
Silica Gel
A Anisole - acetic acid - water (7° : 29 : 1 by vol.)
B Methyl isobutyl ketone - acetic acid-water (2 : 1 : 1 by vol.
upper phase)
C Ethylene dichloride - ethanol-aq. NH^ (sp. gr. 0.88)
D Ether - isopropylamine (95 : 5 v/v)
E Propan-l-ol-aq. NH^ (sp. gr. 0.88) (7 : 3 v/v) •
F Butan-l-ol-aq. NH^ (sp. gr. 0.88) (-2 : 1 v/v upper phase)
Polyamide
G Dimethylformamide - water (l : 1 v/v)
H Methanol - water - dimethylformamide - acetic acid (70 : 20 : 10
. 2  by vol.)
J Methanol - water - dimethylformamide - formic acid (70 : 20 : 10
5 by vol.)
Locating Reagents
A p-Dimethylaminocinnamaldehyde 0.2% (w/v) solution in 2N--HC1
diluted with four volumes of ethanol.
B Naphthoresorcinol 1-0% (w/v) solution in acetone diluted with
four volumes of 10% orthophosphoric acid immediately before use. 
C The Bratton and Marshall diazotisation and coupling reaction
was carried out by spraying the following reagents in sequence, 
the plates or paper being dried in a stream of warm air in 
between each spraying.
(i) Sodium nitrite 0.1% (w/v) diluted with an equal volume 
of 3^ . HC1 immediately before use. .
(ii) Ammoniumsulphamate 0.5% (w/v) aqueous solution.
(iii) N-l-Naphthylethylenediamine 0.1% (w/v) aqueous solution.
Paper Chromatography
Untreated urine samples were chromatographed on paper (Whatman 
3mm) in two solvents.
K Ethanol - water (80 : 20 v/v)
L Butan-l-ol-acetic acid - water (60 : 15 : 25 by vol)
Column Chromatography
, Separations of metabolites in extracts of culture media and
in urine extracts were carried Out on columns of Sephadex LH20 (Pharmacia,
Uppsala, Sweden).
Gas-Liquid Chromatography
Gas-liquid chromatography of a metabolite was carried out 
using a Varian 1200 instrument with flame ionisation detector. The 
column was of glass, 5 ' in length x l/8n 0D packed with gas-chrome Q, 
100-120 mesh,coated with F.60, a p-chlorophenylmethylsilicone (5% v/w) 
as the stationary phase. The operating temperatures were: injection 
port 230°, column oven 180°, detector 250°. The carrier gas was 
nitrogen (whitespot) at a flow rate of 25 ml/min.
ANALYSES
Reverse Isotope Dilution Analysis
The pooled twenty-four hour mice from a batch of four orally 
dosed mice (115 mg/kg) was divided into two equal portions. One was 
submitted for activity testing in vitro, the other was extracted three 
times with an equal volume of ethyl acetate at pH 12.0. Under these 
conditions dinitroindazole can be quantitatively extracted, (mean recovery 
9 8.9% from three control urines spiked at 20pg/ml). Unlabelled 
dinitroindazole (5OO mg) in an excess of isopropanol was added to the 
extract and the mixture heated on a steambath to effect solution.
The compound was recrystallised four times from isopropanol. Specific
activity determinations were made after each recrystallisation by 
combustion of duplicate samples (5mg) to H O  coupled with liquid 
scintillation spectrometry.
Spectroscopic Analysis and Radiochemical Analysis
Full details of instrumentation and methods have been
described previously in earlier chapters.
Quantitative Determination of Radioactive Metabolites
Radioactive metabolites were separated on silica gel thin layer
plates developed in the solvent system which gave the optimal resolution
for the particular metabolite under determination. Areas of silica
were removed by scraping and counted in toluene scintillator plus .3%
(v/v) methanol when solution counting efficiencies were assumed. To
overcome the errors due to self-absorption which occur when tritium
labelled material is incompletely eluted into the scintillation fluid,
polar metabolites were determined by combustion of silica after pelleting
3with a little sucrose in filter paper. The H_0 evolved was then counted 
in NE 250 (dioxan) scintillator.
TUBERCULOSTATIC ACTIVITY TESTING
Pooled urine samples and urine extracts from batches of dosed 
and undosed mice were tested for tuberculostatic activity in vitro 
against Mycobacterium tuberculosis strain H37 Rv by Mr. K.J. Stevens 
of the Pfizer Biochemical Research Group.
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RESULTS
Tuberculostatic Activity of Urine
The results of testing urine samples and urine extracts from 
dosed and undosed control mice for tuberculostatic activity in vitro 
are given in Table 5*2.
Table 5 . 2
The Tuberculostatic Activity in Vitro of Urine Samples, from 
Mice Dosed Orally with Dinitroindazole and of Urine Samples 
from Undosed Control Mice
Test No. Sample No. Mice 
in batch
„ Dose 
(mg/lcg)
Activity Maximum * 
Dilution
1 urine 4 115 + 4
urine 4 - - -
2 urine 4 130 + 4
urine 4 - + 2
3 urine 3 150 + 4
urine 3 - + 2
4 acid
extract
3 150 + 8
acid
extract
3 + 4
The highest dilution of urine or extract preventing growth 
of Myco tuberculosis in a liquid medium, e.g. 1 in 2, 1 in 4, 
etc.
Reverse Isotope Dilution Assay of [ H] - Dinitroindazole in Urine
The specific activity of “ dinitroindazole after successive
recrystallisations is shown in Fig. 5*2.
1-
0
1 2 3 4
Recrystallisations
Fig. 5.2. Specific activity of dinitroindazole after four successive
recrystallisations.
After four recrystallisations the specific activity was still falling 
suggesting that no unchanged drug was excreted. If the specific activity 
after the fourth recrystallisation be accepted as a maximum value, then
0 .34% ^he dose appeared in urine as unchanged drug at a concentration 
of ^ 3.9p.g/ml.
When tested in vitro the urine was found to be tuberculostatic 
at a dilution of 1 in 4- The maximum concentration of dinitroindazole 
was therefore in the region of 1.0 p,g/ml. As the compound has an M.I.C. 
of 12.5 p-g/ml the activity found in urine could not be attributed to the 
unchanged drug and the working hypothesis that the drug is converted to 
a more active species in vivo seemed to be confirmed.
Subsequent testing of further urine samples at a later date 
indicated that the inactivity of control urine on the first occasion of 
testing was quite fortuitous. Control urines were found to be active at 
a dilution of 1 in 2,a mere twofold difference in activity from test samples, 
which is of little significance where a serial dilution technique is 
employed.
Urine Fractionation
Pooled twenty-four urine samples from two batches of four orally 
dosed mice were fractionated according to Scheme I (vide supra)* The 
urinary recovery of radioactivity in 48 hours and the relative amounts of 
radioactivity associated with each fraction are shown in Table 5*3*
Table 5*3
Recovery of Radioactivity in Mouse Urine and Distribution in
o
Urine Fractions following Oral Doses of C Hi - Dinitroihdazole
Batch 1 2
Dose mg/kg I30 155
Urinary Recovery of Radioactivity 
(% of dose in O- 4 8 hours) 44*4 25*9
Radioactivity % in Bases 0 . 9 4-3
Neutrals 1 0 .5 13*6
Acid I
Urine Fractions:
2 4 . 2 1 6 . 6
Acid II 32.9 39.7
Aq. Residue 31*5 2 3 . 8
IDENTIFICATION OF METABOLITES 
(i) Microbial Metabolite
The need to isolate sufficient material not only for 
identification but also for activity(testing presented problems for 
a combination of reasons. Primarily, the size of the test species,
i.e. mouse, and the safe maximum dose level meant that relatively 
small amounts of the drug could be administered, and secondarily, the 
urinary recovery of drug and/or metabolites rarely exceeded 30% the 
dose.
Man|y bacterial species are able to use drug molecules as
i
substrates for a wide variety of reactions, which may be energy yielding  ^
or merely serve as a means of detoxication. The gastro-intestinal flora 
are particularly versatile in this respect and contains an unusually 
large assortment of different species, more than 60 having been isolated 
from the intestinal tracts of healthy animals and man, (Donaldson 1 9 6 4)- 
The possibility of using micro-organisms to produce metabolites 
similar to those excreted in the urine of dosed mice with a minimum of 
effort and perhaps in sufficient yield for both identification and testing 
was therefore most attractive. >
The metabolism of dinitroindazole in vivo is most likely to 
involve reduction of one or both of the nitro groups and/or aromatic 
hydroxylation and both of these types of reaction are known to be 
catalysed also by microbial enzyme systems.
Reduction of the nitro group in chloramphenicol has been 
demonstrated by cultures of Bsch. coli (Smith and Worrell 1950) and 
Proteus vulgaris (Smith and Worrell 1949), both common intestinal 
inhabitants; and Saz and Slie (1954) later described the properties of 
an enzyme system obtained from Esch. coli which reduced a number of simple 
organic nitro compounds.
Aromatic hydroxylation of tryptophan in the 5 position by 
whole cell suspensions of Chromobacterium violaceum was reported by 
Mitoma et al (1956) and Contractor et al (1964) found that hydroxylation 
occurred also in the 6 position under the same incubation conditions.
Accordingly, dinitroindazole was incubated with a mixed culture 
of rat faecal bacteria and after a suitable period of incubation, a thin 
layer chromatographic comparison of the culture fluid and extracts of 
urine from dosed mice was made, revealing the common presence of bright 
yellow material which appeared to be a major microbial metabolite and which was 
later shown also to be the major urinary metabolite in mice.
It was isolated as previously described and the identification 
and proof of structure of this metabolite now follows.
Mass Spectroscopy
A 70 'eV mass spectrum was obtained at a source temperature of 
170O by direct insertion probe. A simplified line diagram is shown 
(Fig. 5.3).
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Fig* 5*3* Simplified low resolution mass spectrum of a microbial
metabolite of dinitroindazole
The molecular ion peak is also the base peak and occurs at 
m/e 178, this being 3^ mass units less than that of dinitroindazole 
(Mol. Wt. 208), and consistent with reduction of one nitro group to an 
amino group. Principal fragment ion peaks at m/e 1 32 ,10 5 and 78 and 
a peak of .lesser abundance at m/e 148 are associated with the 
fragmentation pathway outlined below (Fig. 5»4)f each loss being 
confirmed by a metastable ion peak.
V '
Fig. 5-4
The occurrence of fragment ion peaks at M - 3 0 (M-NO) and
M- 4 6 (M-NO ) is a general feature of the mass spectra of aromatic nitro
compounds, (Budzikiewicz et al 1967)* Losses of 27 mass units are
almost certainly due to expulsion of HCN, a very stable neutral molecule.
Such losses are typical of aniline and unsubstituted aromatic nitrogen
heterocycles (Budzikiewicz et al 1 9 6 7)#
Elemental analysis (C, H and N) is fully consistent with a
proposed structural formula of C„H^N 0_ and the metabolite is therefore
7 0 4 2
concluded to be one of two possible'structural isomers (5 . 2  and 5 »3 )»
NO
2
NH
2
(5-2) (5-3)
Nuclear Magnetic Resonance Spectroscopy
A 60MHz nmr spectrum was obtained in deuteromethanol (Fig. 5*5) • 
The chemical shifts and probable assignments of the aromatic proton 
signals are shown in Table 5*4»
Table 5 . 4
Chemical Shift (V) of the Aromatic Protons
Y
H Multiplicity J(Hz) Assignment
1 . 8 0 1 Singlet - Proton at C- 3
1.90 1 Doublet 2.5 ?Proton at C- 4
2.55 1 Doublet 2.5 ?Proton at C- 6
The nmr spectrum confirms the presence of three aromatic protons.
A singlet at 1-.8Y is readily assigned as the signal for the proton at C-3 . 
The two doublets which show meta-coupling are due to protons at C- 4  and 
C- 6 but are less easy to assign with certainty as the analytical data allows 
only the certain conclusion that the metabolite is a mono-nitro, mono-amino 
species, and affords no help in differentiating the two possible isomers.
Elvidge (1967) has compiled tables of the approximate chemical 
shifts of benzene protons (Y2.73) caused by various ring substituents 
from which the data in Table 5-5 has been abstracted.
Table 5-5
Approximate Shifts (Y) in the Position of Benzene Protons 
caused by Substituents
Substituent ortho met a para
-N0„
2 -1 . 0 -0.3
-0 . 4
-NH
2 0 . 8
O . 1 5 0.4

The approximate calculated chemical shift for the C- 6 proton 
based on these values is 2 .68Y  irrespective of the positions of the nitro 
and amino groups. The calculated value for the proton at C- 4  is 3 -28Y  
where it lies ortho to an amino group and 2 .28Y when adjacent to a nitro 
group. From these predicted values it might be concluded that the 
spectral data obtained are more compatible with the structure shown in 
(5 *2) but there remains a reasonable element of doubt.
Proof of Structure
It had been noted* that when dinitroindazole was methylated at 
N-l its mass spectrum (Fig. ,^6) was characterised by a large M-17 fragment 
ion peak. This peak probably arises from a loss of OH by a hydrogen 
rearrangement p r o c e s s  involving the N-methyl group. . . • „
Similar losses of hydroxyl radicals which have been substantiated 
by deuterium labelling are a characteristic feature of some ortho 
substituted aromatic nitro compounds, e.g. o-nitro-aniline and o-nitro-
toluene (Meyerson et al 1966).
130
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Fig. 5*6. Low resolution mass spectrum of N-l-methyl-dinitroindazole.
* Observation made by Drs. J.D. Hardstone and E.B. Mullock
Therefore it was decided to methylate the metabolite and 
to examine its mass spectrum. A nitro group at C-7 should result in 
a similar loss of OH which could not occur if the amino group were 
at C-7. To overcome the difficulty of distinguishing the two possible 
methyl derivatives, an authentic sample of N-l-methyl-dinitroindazole 
was to be reduced microbially to furnish a reduced metabolite with a 
methyl group fixed at N-l for comparison.
However, when N-l-methyl-dinitroindazole was incubated with 
a culture of gut micro-organisms two mono-amino, mono-nitro species 
were produced, which were isolated as previously described.
Their mass spectra (Figures 5*7 and 5*8) show common molecular 
ion peaks at m/e 192, consistent with mono-nitro reduction, however, 
the fragmentation patterns are quite dissimilar. As expected, one 
species is seen to lose OH from its molecular ion (Figure 5*8 m/e 175= 
M-1 7) which is confirmed by the presence of a metastable peak (M* =
159*5 ), whereas the other shows no significant loss of this
type. They are therefore concluded to be isomers with structures as
shown (Figures 5 . 7  and 5*8) on page 1 3 0.
Nmr spectra of both isomers were obtained in deuterated acetone 
(Figures 5*9 and 5 .10). The chemical shifts observed for the aromatic 
protons (Structures II and III) are compared with the values obtained  ^
for the microbial metabolite of dinitroindazole (IV) and N-l-methyl- 
dinitroindazole (I), also with predicted values in Table 5*8. Assignments 
can now be made with confidence. The C- 3 proton signal is readily 
assigned in all spectra (sharp singlet). Signals due to C - 4  and C- 6  
protons occur as doublets (J = 2.5 Hz). Where the amino group lies ortho
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Figure 5.7. Low resolution mass spectrum of 1st microbial metabolite 
11-1-methyl-dinitroindazole.
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Figure 5 .8 . Low resolution mass spectrum of 2nd microbial metabolite 
N-l-methyl dinitroindazole.
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to both protons (Structure II), both signals move upfield and as the 
nitro group ortho to C- 6  will have a strong deshielding effect the 
higher signal is assigned to the proton at C-4 / In structure III the 
C- 4  proton will be deshielded to a greater extent than C-6  and the 
signal for this will' be the one at lower field.
The chemical shifts of protons in Structure III which has been 
authenticated and in Structure IV, the microbial metabolite of dinitro­
indazole are seen to be in good agreement proving beyond doubt that its 
structure is correctly assigned.
The observed and calculated r values are also seen to be in 
fairly good agreement. •
Mass Spectral Evidence for Structure
The original plan to identify the microbial metabolite by mass 
spectroscopy of a methylated derivative was carried through. After 
methylation overnight with a freshly distilled ethereal solution of 
diazomethane, the products were co-chromatographed on a silica gel thin 
layer plate with the authentic sample of N-l-methyl-5-nitro-7*-amino- 
indazole developed in solvent D.
One of the products was a yellow band identical in Rf value to 
the authentic marker. A mass spectrum of this material showed no M-17 
peak and was a duplicate of the marker spectrum shown in Figure 5*7- 
Identification of Mouse Urinary Metabolites
(ii) Metabolite II
Thin layer chromatogram of neutral extracts of mouse urine 
revealed the presence of a single yellow radioactive metabolite 
(Metabolite II). It gave an instantaneous purple colour when sprayed 
with the cinnamaldehyde reagent but could not be diazotised and coupled
in the Bratton and Marshall reaction. Its chromatographic behaviour 
(Rf) on silica gel thin layers was identical to the microbial metabolite 
in three solvents; A, O.6 5, B, O .9 6 and C, 0 .5 5.
Light Absorption Spectroscopy
Light absorption spectra recorded in methanol in the presence 
of acid and base were similar to spectra of 5-nitro-7”aminoindazole showing 
absorption maxima at 270 nra (HCl) and at 286 nm (NaOH). .
Mass Spectroscopy
A mass spectrum of metabolite II was obtained which was identical
\
to the spectrum of the microbial metabolite.
It was therefore concluded that metabolite II and the microbial 
metabolite were identical.
The Effects of p H  011 the Extraction of Radioactivity and of Metabolite II 
Thin layer chromatograms of the extract designated 'Acid 1* 
also contained only one metabolite. On the basis of similar light 
absorption spectrum, mass spectrum and identical chromatographic 
properties it also was identified as metabolite II. Such a finding 
suggested that metabolite II must be excreted at least in part as an 
acid-labile conjugate. An experiment was thus designed to study the 
effects of increasing hydrogen ion concentration on both the total amount 
of radioactivity and the total amount of metabolite II extractable from 
twenty-four urine samples which had been collected into receivers 
containing a little saturated sodium bicarbonate to stabilise acid- 
labile metabolites.
Urine samples were then exposed to increasing concentrations of 
acid for a ten minute period prior to solvent extraction as described 
in the methods section. Total radioactivity extracted was determined
by liquid scintillation counting in scintillator A, metabolite II \-ras 
assayed by combustion of radioactive silica after separation of 
metabolites on silica gel thin layers developed in solvent A.
The results are shorn in Tables 5-7 and 5*8 and also in 
graphical form in Figs, and 5-12.
Table 5-7
The Effect of Increasing Hydrogen Ion Concentration on the . 
Amount of Radioactivity Extracted from the Pooled Twenty- 
four Hour Urines of Orally and Intraperitoneally dosed Mice
pH
°Js Radioactivity Extracted
oral (3) Intraperitoneal (3 )
7.0 12.8 I9 .7
6.0 14.0 21.1
5.0 18.9 2 6 .6
4.0 39.9 5 0 .2
3.0 72.2 75-3
2.0 73.2 83.9
1.0 8 5 .4 8 6 .9
Figures in parentheses indicate number of mice in batch
Table 5.8
The Effect of Increasing Hydrogen Ion Concentration on 
the Amount of Metabolite II Extracted from the Pooled 
Twenty-four Hour Urines of Orally and Intraperitoneally 
Dosed Mice Expressed as Percentage of Total Urinary
Radioactivity
P H  .
% Metabolite II '
Oral (3) Intraperitoneal (3 )
7.0 7.4 7.9
6.0 7.4 - • 8 .3
5.0 1 0 .7 1 0 .8
4.0 23.3 23-4
3.0 4 0 .2 31.6
2 .0 39.2 34-3
1 .0 49.0 40.7
Figures in parentheses indicate number of mice in batch
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Fig. 5*11* Urinary Radioactivity % extracted following oral (*--- #)
and intraperitoneal (•— ---   •) administration of C^H3-
dinitroindazole
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Fig. 5*12. Metabolite II % extracted following oral (•--- •) and
intraperitoneal (•------ •) administration of [^H]-
dinitroindazole
The amount of radioactivity extractable from urine after prior 
exposure of urine to increasing concentrations of cold acid showed a 
high degree of correlation with acid strength. That this increase is 
not merely due to the extraction of acidic species is evidenced by the 
increased amounts of Metabolite II extractable after acid treatment 
which shows the same high correlation with acid strength (Metabolite II 
is virtually a neutral compound and can be quantitatively extracted at 
all pH values below *^13.0. '
Reduction of Dinitroindazole in vivo by the Gut Microflora .
The potential of the intestinal microflora to reduce nitro 
compounds has long been recognised (Bray et al 1953) and reduction of 
dinitroindazole by rat gut micro-organisms has been demonstrated in vitro. 
In order to assess the possible importance of the gut microflora in 
reduction of the drug in vivo the urinary excretion of Metabolite II was 
measured both after oral administration to mice and after dosing by 
intraperitoneal injection. At the time of this experiment this appeared 
to be a point of some importance as several close analogues of this drug 
were found to be active when given orally but inactive by intraperitoneal 
injection. (Metabolite II was later shown to be an inactive metabolite).
For convenience these results are also shown in Tables 5 *7 and 
5*8 and Figs. 5.11 and 5*12, whilst Table 5*9 shows the comparative 
recoveries of radioactivity in urine after dosing by both routes.
The urinary recovery of radiqactivity in both orally and 
intraperitoneally dosed mice was essentially similar. Absorption of 
drugs from the peritoneal cavity is primarily through the portal 
circulation (Lukas et al 1971) thus by-passing the gut. The amount of 
metabolite II excreted after intraperitoneal administration of drug was 
41/6 compared with 49% after oral administration, a difference which is
Table 5.9
Recovery of Radioactivity in Mouse Urine Following Oral
O
and Intraperitoneal Administration of [ H] - Dinitroindazole 
Expressed as Percentage of Dose
Route of Dose Time of Collection (hours)
Administration . mg/kg 0 -2 4 24-48 O-4 8 Total
Oral 140 25.5 8 .8 34.3
Intraperitoneal 55 31.1 5.5 3 6 .6
probably not significant and which would suggest that reduction in vivo 
occurs chiefly in the liver. It is conceivable that metabolite II could 
be produced by the gut microflora after intraperitoneal dosing but this 
would require extensive biliary excretion of the unchanged drug itself, 
an unlikely occurrence in view of its non-acidic nature and relatively 
low molecular weight (2 0 8), two factors of prime importance in the 
biliary excretion process (Millburn et al 1 967)#
(iii) Metabolite III
■When'urine samples were made progressively more acidic the 
increased amount of extractable radioactivity was paralleled by the 
extraction of increased amounts of Metabolite II confirming the presence 
in urine of an acid-labile precursor (Metabolite III), It was 
suspected that Metabolite III might well be either an N-glucuronide and/or 
an arylsulphamate both of which are known to be acid-labile conjugates 
(Boyland et al 1957)*
Chromatography
N-glucuronide and N-sulphate derivatives of the microbial 
metabolite were prepared as described and used as reference marker 
compounds for thin layer chromatography of neat urine on silica gel 
and also on paper (Whatman 3™^)•
Table 5»IQ
Rf Values and Colour Reactions of Mouse Metabolite III 
5-Nitro-7-aminoindazole, 5-Nitro-7~glucuronosvlaminoindazole and 
5-Nitro~7-sulphaminoindazole chromatographed on Silica Gel in 
Solvents E and F and on Paper in Solvent H
Compound
Solvents Sprays
E F H DMAC Naphthoresorcinol
Metabolite III 0 .1 1 0 .0 5 0.33 Purple 
(1 -2 mins)
Slate-blue
5~Nitro-7-glucuronosylamino-
indazole 0 .1 1 0 .0 5 0.33 Purple 
(l- 2  mins)
Slate-blue
5~Nitro-7“Sulphaminoindazole 0.74 0 .3 0 0.57 Purple 
(5 mins) -
5-Nitro-7-aminoindazole 0.99 0.73 0.79 Purple
(immediate) -
On all of the chromatograms a band was seen with a similar 
mobility to the synthetic glucuronide conjugate of metabolite II. Its 
behaviour with sprays was also identical. It gave a positive colour 
reaction with the naphthoresorcinol spray reagent for glucuronides and it 
developed a purple colour with the cinnamaldehyde reagent, full colour 
development requiring 1-2 minutes. There was no chromatographic evidence 
for the excretion of a sulphate conjugate of metabolite II.
Enzyme Hydrolysis
Urine was incubated with a brand of (3-glucuronidase active at 
pH 7*0 (as described in the experimental section) to avoid exposure to 
acid. The effect of this treatment on the extraction of radioactivity 
and of metabolite II is shown in Tables 5 « H  and 5»12.
The results of this experiment show that although hydrolysis 
of metabolite III is incomplete, 80% of the total amount of metabolite 
II excreted can be extracted at neutral pH after enzyme treatment compared 
to lj.0% extracted from the untreated control urine. The figure of 
obtained for the control sample is high. This is because the urine sample 
used in this experiment.had been stored for several days after collection 
as voided, i.e. without addition of sodium bicarbonate to stabilise the 
conjugate.
Table 5>11
The Effect of (3-glucuronidase Pretreatment on the amount of 
Radioactivity sequentially extractable from 1 ml of mouse 
urine* at pH 7.0 and at pH 1.0
TEST (Enzyme Treated) CONTROL (Untreated)
Counts Extra­
cted (dpm)
Percentage of 
Urinary activity
Counts Extra­
cted (dpm)
Percentage of 
Urinary Activity
pH 7.0 2 ,3 3 0 ,8 0 0 50.98 1,2 6 7 ,1 4 0 27.72
pH 1.0 1,4 9 2 ,1 2 0 32.64 2,6 1 5 ,8 8 0 57.22
Totals 3,822,920 8 3 .6 2 3,983,020 84.94
* Urinary Radioactivity *= 4,571,300 dpm/ml.
Table 3*12
The Effect of fi-glucuronidase Pretreatment on the sequential 
Extraction of Metabolite II from Mouse Urine at pH 7.0 and at pH 1.0
TEST (Enzyme Treated) CONTROL (Untreated)
Percentage
Extract
of Percentage of 
Urinary activity
Percentage of 
Extract
Percentage of 
Urinary Activity
pH 7.0 72.5 37.0 6 7 .6 18.7
pH 1.0 2 8 .0 9.1 49.1 2 8 .1
Total - 4 6.I - 4 6 .8
(iv) Metabolite IV
Thin Layer Chromatography
Chromatography of the *Acid II* extract of mouse urine revealed
a major radioactive metabolite (IV) which appeared as a yellow spot when
chromatographed in an acid solvent, but in basic solvents changed to a
deep reddish brown colour. It gave no colour with cinnamaldehyde and
its chromatographic behaviour was identical to an authentic sample of
synthetic 3~bydroxy-5,7-dinitro-indazole. Rf values on silica gel in
solvents were? A, 0.75, E, 0.7.6' and F, O.4 9.
Light Absorption Spectroscopy
Metabolite IV was isolated after chromatography in solvent E,
elution with methanol, and further chromatography in solvent A. Light
absorption spectra of Metabolite IV were obtained for methanolic
solutions in the presence of acid and base and compared with similar
spectra of authentic 3“bydroxy-dinitroindazole. The spectra were closely
similar, slight differences in the respective wavelength maxima of
metabolite and authentic material being probably due to traces of
impurities still present after clean-up. The phenolic nature of the
metabolite was confirmed by the large bathochromic shift in •y seenJ max
on ionisation: 358 nm MeOH/HCl to 43® MeOH/NaOH.
Mass Spectroscopy
No satisfactory mass spectrum could be obtained. This was not 
entirely unexpected and was probably due to an insufficiency of material 
as a comparatively large amount of the synthetic compound was needed to 
obtain a spectrum on account of its extreme involatility.
Additional Evidence for Co-identity of Metabolite IV and 3-Hydroxy- 
dinitroindazole
Although all of the available evidence suggested the Metabolite 
IV must be a dinitrophenol viz#, solubility in sodium bicarbonate, a 
light absorption spectrum characteristic of a phenol and its failure 
to give a colour with p-dimethylaminocinnamaldehyde, the slight differences 
in the light absorption spectrum of the metabolite and of the authentic 
3-hydroxy reference compound prevented the unequivocal conclusion that 
the two were identical although they could not be differentiated by thin 
layer chromatography in three solvents.
In order to strengthen the evidence two additional techniques 
were used to compare the unknown and reference samples.
Chromatography on Polyamide Thin Layer
Phenols are known to bind strongly to polyamides, powerful 
hydrogen bonds being formed between phenolic hydroxyl groups and the 
amide groups of the adsorbent, and chromatography of phenolic compounds 
has been used for the isolation of various naturally occurring materials. 
Among numerous examples quoted by Endres and Hormann (1963) are the 
tannins of sprucewood bark, hydroxystilbenes from Eucalyptus wandoo 
and the pigments of beets.
NO,
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(5.4) <5.5)
If the mouse phenol is not 3~hydroxy-dinitroindazole it is 
most probably an isomer of it i.e. a 4“ or 6-hydroxy compound and in 
both cases intramolecular hydrogen bonding is possible which is precluded 
when the hydroxyl group is in the 3 position (5 * 4  and 5 *5)* The 
internally bonded phenol should therefore have a greater mobility on a 
polyamide layer than the non-bonded phenol when chromatographed in an 
appropriate solvent*
Polyamide thin layer plates were prepared accordingly as 
described and Metabolite IV and authentic 3**hydroxy-dinitroindazole 
were co-chroraatographed in three solvents. Three isomeric model compounds 
were also run to check the potential of the method; ortho, meta and 
para-nitrophenol. The results appear in Table 5*13*
Table 5*13
Rf Values of Metabolite IV, 3~‘Hydroxy-dinitroindazole and 
Three Nitrophenols on Polyamide Layers
Compounds Solvents
G H J
Metabolite IV 0 .0 2 0 .0 9 0 .1 8
3-Hydrosy-dinitroindazole 0 .0 2 0 .0 9 0 .1 8
o-Nitrophenol 0 .2 8 0 .6 1 O .5 6
m-Nitrophenol 0 .2 0 0.49 O .4 2
p-Nitropheno1 0 .2 0 0*49 O .4 2
Metabolite IV and 3~hydroxydinitroindazole were located at 
the same Rf in three different solvents providing added evidence for 
co-identity. As expected o-nitrophenol had a greater mobility than 
either of the other two isomeric nitrophenols which were not separated 
from each other.
(ii) Gas-Liquid Chromatography
Trimethylsilyl ether derivatives of Metabolite IV and 3~hydroxy-dinitroindazol 
were prepared according to the method of Sweeley et al (1963)* Solutions 
of both materials in methanol were evaporated to dryness under a stream 
of dry nitrogen and then dissolved in two drops of dry pyridine (KOH). 
Hexaraethyldisilazane (0.1 ml) and trimethylchlorosilane (O.O5 ml) were - 
then added in rapid succession. After mixing and stoppering the tubes 
were allowed to stand at room temperature for ten minutes. The reaction 
mixtures (2 pi) were then chromatographed directly without further 
treatment.
Column and Operating Conditions .
Solid Support: Gas-Chrome Q 1 0 0 -1 2 0 mesh 
Stationary Phase: 5% F60 (p-chlorophenylmethyl silicone)
Injector Temperature: 230°
Column Oven Temperature: 180°
Detector Temperature: 250°
Chart Speed: 10M/hour
It was expected that under the derivatisation conditions 
employed only the phenolic-OH would be silylated and when the derivatised 
standard reference material was chromatographed a single peak emerged 
with a retention time of 8 * 24" (Fig# 5*13 (a)). £
When the mouse metabolite was chromatographed at the same 
range and attenuation settings several small peaks were seen followed 
by a large peak with a retention time of 8 ' 28” (Fig. 5#*3 (b)).
(b)(a)
Fig. 5.13 Fig. 5 .I3
By virtue of its similar chromatographic properties on silica 
gel and on polyamide layers, the similar retention time of its trimethyl 
silyl derivative and the close similarity of its light absorption 
spectrum Metabolite IV was concluded to be identical to the authentic 
3-hydroxy dinitroindazole.
Quantitation of Metabolites II, III and IV
The results of quantitative determination of the three 
metabolites isolated are given in Table 5*14*
Table 5*14
Urinary Excretion of Three Metabolites following Oral
O
Administration of [ H] - Dinitroindazole to Mice
Metabolite Urinary Radioactivity %
Exp. 1 Exp. 2 Exp. 3 Exp. 4
II
III
II + III (Total) 
IV
10.5(4)
34.7(4) 46.1(3) 49.0(3)
8.5(3)
12.9(8)
42.4(8)
55.3(8)
9.6(8)
- Not determined
Figures in parentheses indicate number of animals in batch.
Tuberculostatic Activity of Metabolites II and IV
vitro MIC^ s of metabolites II and IV against Myco­
bacterium tuberculosis strain H37 Rv were 6.25 an<* 12.5 V-g/ml respectively. 
Neither metabolite had any significant activity in vivo against experimental 
infections in mice by either oral or intraperitoneal dosage routes.
Minor Metabolites
Unidentified Glucuronide
When extracts of acidified urine were chromatographed in Solvent A 
a band of radioactivity remained at the origin which accounted for 5*7%
of the urinary radioactivity, and appeared to be associated with a 
band of ultraviolet light absorbing material (2 5 4 nm) and which also 
gave a positive slate-blue colour reaction when sprayed with the 
naphthoresorcinol reagent for glucuronic acid. This band was not 
found after prior treatment with (3-glucuronidase. Reference to 
Tables 5.H shows that after such treatment 50*98% of the radioactivity 
in urine could be extracted at pH 7.0 compared to 27.72% before­
treatment an increase of some 23.0%. Table 5*12 shows that Metabolite II 
accounts for about 18.0% of this extra activity. The remaining 5*0% 
is probably due to the aglycon of the conjugate recognised by thin layer 
chromatography, this figure being in good agreement with that found for 
the glucuronide band.
On chromatography of the pH 7.0 extract in solvent A a band 
of very weak ultraviolet light (2 5 4 nm) absorbing material was found 
at Rf O .3 5 which was also just visibly yellow to the naked eye but there 
was insufficient material to obtain a light absorption spectrum. On 
spraying with DMAC it appeared to give a weak reddish-purple colour 
reaction although this was difficult to interpret as a small amount of 
urea was located at the same Rf which gives a pink colour with this 
spray reagent.
Assuming this colour reaction to be a genuine one, the inference 
is that the aglycon must possess an aromatic amino group. Assuming it 
also to be phenolic, which is most probable, the fact that it could be 
extracted at pH 7.0 seems to confirm the reduction of at least one of 
the nitro groups, as a dinitrophenol being a relatively strong acid would 
not be expected to partition into an organic solvent at neutral pH, 
e.g. the pKa of 2,4-dinitrophenol is 4 .0 1 (Sykes 1970).
If these assumptions are correct then the glucuronide recognised 
in mouse urine is a conjugated aminonitrophenol. It does not appear to 
be excreted in urine in the unconjugated form to any significant extent. 
Its possible structure will be discussed later in the context of a 
similar metabolite isolated from rat urine.
The results of metabolism studies in mice described in this 
chapter will, for reasons of convenience, be discussed together with the 
results of a comparative study in rats described in the following chapter.
CHAPTER SIX
The Metabolism of Dinitroindazole 
in the Rat
Introduction
Experimental (a) Reference compounds
(b) Isolation of urinary metabolites 
Results (a) Excretion
(b) Identification of Metabolite V
(c) Possible Identity of Metabolite VI
Discussion
INTRODUCTION
As a possible aid in identifying minor metabolites of 
dinitroindazole in the mouse, the compound was administered orally 
to rats in the hope of obtaining similar metabolites in greater 
yield. However when rat urine was examined after a radioactive dose 
differences in both the manner and pattern of metabolites were 
revealed. At this point in the investigation the identification of 
further mouse metabolites ceased to be a priority and the opportunity
was taken to examine more closely two metabolites found in rat urine
> '
which appeared to be totally absent from the urine of orally dosed mice.
This chapter describes the isolation of two further urinary 
metabolites of dinitroindazole. One of these has been positively 
identified; the possible structure of the other is discussed.
EXPERIMENTAL
Reference Compounds
3-Hydroxy- amino-nitro-indazole was prepared from 3“*Hydroxy-5-7“dinitro- 
indazole by reduction with titanous chloride. 3“Hydroxy-5-7-dinitro- 
indazole (448 mg) was dissolved in methanol (50 ml), and titanous 
chloride solution added with stirring (12.0 ml of an approximately 
1.0M solution in HCl) at room temperature. The reaction mixture was 
allowed to stand for 2 hours and then evaporated at 37° to remove the 
methanol. The volume was made up to 100 ml. with distilled water and the 
pH adjusted to pH 6.0 prior to extraction three times with equal volumes 
of ethyl acetate. The extract was chromatographed on a column of 
sephadex LH20 in methanol (4 0 x 3 cm). A prominent initial yellow band proved 
on elution to be Unchanged starter material. This was followed by a 
well resolved orange band, which was evaporated yielding a purple-brown 
gum. Attempts at recrystallisation were unsuccessful and solid material 
was finally obtained by precipitation from methanolic solution with 
ethyl acetate. The solid was filtered and washed successively with 
ethyl acetate, methanol and ether. The final product was apparently pure 
by thin layer chromatography. Yield after drying 27«25 mg. The compound 
did not melt but gradually decomposed above 270°. Found C, 43*3, H, 3*1,  
requires C, 43.3 ,  H, 3.1%.
3-Hydroxy-5-nitroindazole was obtained by two synthetic routes.
Route A: by condensation of 2-chloro-5-nitrobenzoate with hydrazine
hydrate (Kenner and Withara, 1921). 2-Chloro-5-nitrobenzoic acid (5g) 
was refluxed for 24 hours with dry methanol (100 ml) and concentrated 
sulphuric acid (.2ml) to yield methyl-2-chloro-5-nitrobenzoate (3«3g) 
which was separated from the unesterified acid by extraction with 
saturated sodium bicarbonate. The ester was dissolved in warm ethanol 
(1 0 0 ml) and hydrazine hydrate cautiously added (3 *5 nil of a 60% w/w
solution). The mixture immediately turned an orange-red colour, and
on heating gently for 1 hour changed to a dark port-wine colour. After
evaporation the mixture was taken up in saturated sodium carbonate and
washed with ethyl acetate. The aqueous layer was then acidified with
2^1HC1 and extracted again with ethyl acetate. On evaporation of the
extract a yellow solid was obtained which was recrystallised twice
from isopropanol. Yield 615 nig, m.p. 270° with decomposition (literature
value 273°) Found: C, 47«3, H, 3*1, N, 23.7, C H N 0 requires
7 5 3 3
C, 46.9, H, 2.8, N, 23*5% Mass spectrum: M+ at m/e 179*
Route B: by deamination of 3-hydroxy-aminonitroindazole using the
method of Mai (1902). The 3“hydroxy-aminonitroindazole (25«0 mg) obtained
above was dissolved in hypophosphorous acid 50% (v/v) aqueous solution
(5*0 ml). The solution was cooled in ice and sodium nitrate (10.0 mg)
added drop-wise as a solution in a little distilled water. The reaction
mixture was allowed to stand at room temperature for 2 hours followed by
refrigeration overnight at 4°* The pM the mixture was adjusted to
7.0 and two extractions made with ethyl acetate. A thin layer chromatogram
of the extract on silica gel developed in solvent A with 3“hydroxy-amino-
nitroindazole as a reference marker, showed several yellow spots, the
largest at Rf 0.50, ahead of the reference starter material at Rf O.4O.
This spot gave no colour when sprayed with the cinnamaldehyde reagent.
The extract was then applied to a column of Sephadex LH 20 (20 x 2cm)
and eluted with methanol. A yellow band was eluted which appeared pure
by t.l.c. and when evaporated to small volume and refrigerated overnight
yielded fine crystalline needles (2 .5  mg) which melted at 268° with
decomposition. Found: C, 47*4, H, 3«1, N, 23*2, C M  n o  requires
0  3 3
C, 4 6.9, H, 2 .8, N, 2 3.5% Mass spectrum: M+ at m/e 179* Infra red 
spectrum: identical in all respects with the product obtained by direct
synthesis (Route A).
Isolation of Urinary Metabolites
The general methods used for isolation and characterisation of 
metabolites have been described previously (cf Chapter V). The particular 
methods used in isolating two further metabolites from rat urine are 
now described.
Isolation of Metabolites V and VI
The pooled 48 hour urine from four male rats which had received 
unlabelled dinitroindazole (200 mg/kg) was adjusted to pH 5.0, and 
diluted with an equal volume of nKetodase,! (Warner brand of (3-glucuron- 
idase from beef liver free from sulphatase activity) containing 200,000 
Fishman units of enzyme activity. After overnight incubation at 37°, 
the pH was adjusted to 6.0 and the mixture extracted three times with 
an equal volume of ethyl acetate. The organic phase was then washed 
twice with equal volumes of 0.01 14 NaOH. The organic layer with unwanted 
metabolite II was set aside. The aqueous phase was then reacidified 
with 0.1 14 HC1 to pH 6.0 and re-extracted with ethyl acetate three times.
This extract after drying over anhydrous sodium sulphate was 
evaporated to small volume (2-3 ml), loaded on to a column of Sephadex 
LH 20 in methanol (4 0 x 3 C|°) and eluted with methanol. A poorly 
resolved fast running yellow fraction was eluted first, followed by a 
broad major band of yellow/brown material which was itself not completely 
resolved from a bright lemon-yellow band. These three bands were 
collected separately and designated as fractions A, B and C.
After thin layer chromatographic examination of these fractions, 
preparative chromatography was carried out on fractions B and C using 
silica gel layers (2 .0  mm).
Metabolite V
Fraction B was developed in solvent A (anisole-acetic acid- 
water 70:29:1 by vol.)* A yellow band at Rf 0.35'was scraped, eluted 
with methanol and re-chromatographed on silica gel developed in solvent 
F (butan-l-ol-aq. ammonia 0.88 S.G. 1:1 v/v upper phase). A reddish- 
brown band at Rf. O .4 5 was scraped and eluted (Metabolite V).
Metabolite VI
Fraction C was chromatographed first in solvent F and the lemon- 
yellow band at Rf O.3O scraped, eluted and re-chromatographed in solvent A. 
The lemon-yellow band at Rf O.5O was scraped and eluted with methanol. , 
Attempts to recrystallise this material from several solvents were un­
successful. Crystalline material (ca 1.0 mg) was eventually obtained 
from a solution in isopropanol which had stood at 4° several weeks
(Metabolite VI). This solid did not melt, but sublimation occurred at
O /, o
240 and it gradually decomposed at temperatures above 260 .
RESULTS
Urinary Excretion of Radioactivity in Rats after Oral Doses of [^H] - 
Dinitroindazole
After oral administration of radiolabelled dinitroindazole to 
a male rat less than J*0% of the label was recovered in the first twenty- 
four hour urine sample. When an additional 17.4% was found in the 
second day sample the fact was not considered to be noteworthy as such 
results are not infrequent and may be due to urinary retention or a 
degree of oliguria. However, when a further 16.4% appeared in the day
3 sample,delayed excretion was confirmed and an enterohepatic circulation 
was suspected. Subsequent investigations in two other rats confirmed 
this pattern of delayed excretion. The urinary recoveries of radio­
activity from six batches of mice and three rats are compared in 
Table 6.1.
Table 6.1
Urinary Recoveries of Radioactivity in Mice and Rats following
3Oral Administration of C H] - Dinitroindazole
SPECIES MOUSE RAT
Experiment No. 1 2 3 4 5 1 2 3
No. of Animals 4 4 3* 3 8 1 1 1
0-24 Hours 40.3 12.8 25.5 32.2 18.0 6.9 4*6 10.3
24“48 Hours 4.1 13.1 8.7 5.5 6.8 17.4 13.6 16.8
48-72 Hours - - 3.3 2.5 1.3 16.4 3*2 2.2
Total 0-72 Hours 44*4 25.9 37.5 40.2 26.1 40.7 21.4 29*3
* This group of animals received the compound by intraperitoneal 
injection.
It is seen that although the overall recovery of the radiolabel 
in seventy-two hours is essentially of the same order in the two species, 
there is a distinct difference in the patterns of excretion, and the data
obtained in respect of the rat support the hypothesis of biliary 
excretion and enterohepatic recycling of drug and/or metabolites, this 
species being noted as a good biliary excreter (Abou-El-Makarem et al
1967b, Millburn et al 1967)•
This basic difference in excretion patterns suggested that 
dissimilarities in the pattern of excreted metabolites might also be 
found and this was indeed the case. When chromatograms of rat and 
mouse urine were compared (see Fig. 6.1) not only were there obvious 
pattern differences between the two species but slight differences in 
the patterns of metabolites in the 24 and 48 hour rat urine chromatograms 
were also seen. The most striking difference was the presence of a 
bright lemon/yellow radioactive material, not found in mouse urine and 
which accounted for J*ta'12.5% of the urinary radioactivity on the single 
occasion when a quantitative determination was made. A second noticeable 
difference was seen when the rat 48 hour urine chromatogram was compared 
with chromatograms of the 24 hour urine samples of both species developed 
in solvent F. A band of dark red-brown material was present on all 
three chromatograms which corresponded in Rf value to an authentic 
sample of 3“hydroxy-dinitroindazole (XV), running slightly slower on the 
rat 48 hour urine chromatogram and only partially resolved was another 
reddish brown band which was nevertheless subtly distinguishable in 
colour from the faster band. In contrast it appeared to give a colour 
with the cinnamaldehyde reagent although the colour development was 
quite slow and was difficult to interpret due to the presence of urea.
The common presence of radioactive, naphthoresorcinol-positive 
bands at the origin on chromatograms developed in solvents E and F 
seemed to offer the best hope of identifying more mouse metabolites

but it was at this time that the decision was taken to abandon the 
original objectives due to unfavourable toxicity reports on the 
compound*
Identification of Rat Urinary Metabolites
As with the mouse, no unchanged drug vras found in the urine 
of orally dosed rats. Spots corresponding to metabolites II and IV 
excreted in mouse urine were also found on chromatograms of rat urine 
after oral administration of drug. Both were positively identified by 
the methods previously described. Also, a mass spectrum of Metabolite 
IV was obtained which agreed in all respects with a spectrum of the 
authentic synthesised substance.
A spot corresponding in Rf value to the N-glucuronide,
Metabolite III was found on the chromatogram developed in solvent F 
which also gave a blue colour with the naphthoresorcinol reagent, but 
a chromatogram developed in solvent E did not confirm this finding.
Although an area of radioactivity was detected at the Rf of an authentic 
marker no colour was developed with either cinnamaldehyde or naphthore­
sorcinol reagent and it was concluded that metabolite III could not be 
present in significant amount.
Following thin layer chromatography in solvent E, bands of 
silica corresponding to Metabolites II and IV, the lemon-yellow 
metabolite (VI) and the glucuronide band at the origin were removed from 
the plate by scraping and the radioactivity determined by combustion.
Only one red-brown band was seen on the chromatogram which was located 
at the same Rf as Metabolite IV. On spraying with the cinnamaldehyde 
reagent it developed a purple colour confirming the presence of a second 
component V which accounted for the apparent absence of the other red-brown
material noted when solvent F was used as developing solvent* The 
figure given for metabolite IV in Table 6.2 thus includes both entities 
and must be considered as representing only a maximum value rather 
than a true one.
Table 6.2
Quantitative Determinations of Urinary Metabolites of 
Dinitroindazole after Oral Administration to a Rat
Metabolite II IV & V VI Glucuronide
Rf 0.90 O.76 0.60 0.10
% Urinary 
Radioactivity 18.8 4.9 12.5 20.2
No evidence for the excretion of an arylsulphamic acid 
derivative of Metabolite II could be obtained by thin layer chroma­
tography.
Identity of the Second Red-brown Metabolite (Metabolite V)
After thin layer chromatography of rat urine and development 
in a basic solvent system e.g. solvent F, the plate was dried in a 
stream of warm air and exposed to fuming HC1 which as well as inducing 
a colour change in metabolite IV also caused the unknown red-brown 
metabolite to become yellow. No other bands on the chromatogram were 
affected by this treatment. These colour changes appeared to indicate 
the presence of a second nitrophenol. Although Parke (i960) observed 
the direct insertion of a hydroxyl group ortho to an aromatic nitro group
he found only small amounts of 2,4”dinitrophenol (0.1%) after dosing 
m-dinitrobenzene to rabbits, the major phenolic metabolites being 
2-4-diaminophenol (31$) and 2-amino-4-nitrophenol (14%).
These findings suggested that metabolite V would probably 
not be either of the two remaining possible dinitrophenols and its 
apparent reaction with the cinnamaldehyde appeared to confirm this view.
It was therefore concluded that the metabolite was likely to 
be a mononitro-monoaminophenol. As reduction of the 7-nitro group 
and hydroxylation in the 3 position had already been observed it was 
reasonable to conclude that the corresponding aminophenol might also 
be produced by metabolism. However, numerous other aminophenols are 
possible including ortho-aminophenols. These could arise either by 
direct hydroxylation of amines or alternatively might be produced in vivo 
through the intramolecular rearrangement of hydroxylamine intermediates 
formed by reduction of nitro groups. Phenylhydroxylamine has been shown 
to rearrange in acid solution to yield mainly ortho and para-aminophenols 
(Bamberger 1921).
Strong intra-molecular hydrogen bonding of o-arainophenols 
would be expected in acid solution which could perhaps affect the 
condensation reaction with p-dimethylaminocinnamaldehyde, therefore the 
reaction of o-aminophenol with cinnamaldehyde was checked. The colour 
reaction was immediate, suggesting the metabolites of this type would 
give colours with this reagent and that any metabolite failing to give 
an.immediate colour with this reagent would probably not have a free 
amino group.
Clark and Perrin (1964) and Barlin and Perrin (1966) have
published methods for predicting the respective strengths of organic
bases and acids in water. Thus the pK of substituted anilines maya
be predicted from the use of the equations
pK = 4.57 -2.81 (to-)a
where a- is a substituent constant obtained from tables of values for
various substituents in meta and para positions (apparent <r constants
for some ortho substituents are also given but due to steric and
conjugative effects their predictive value is far less reliable).
Similarly the pK of phenols may be predicted using the a
equation:
pK *= 9.92 -2.23 (£cr) . *a
again obtaining c* values from tables.
These equations were used to make approximate estimations of
the pK values for -NH and -OH groups in two possible aminonitrophenols a 2
(6.1 and 6.2) assuming reduction of the 7-NO group which had already 
been shown to occur.
OH
0 N 
2
NH
HO
NH,
(6.1) (6.2)
The pIC of both phenols was calculated to be ^ 8.7 whilst the pK of 
a a
the amino group was calculated to be <^ 2.8 in (6.1) and "'*'3.7 in (6.2).
Urine was therefore extracted at pH 6.0 both before and after treatment 
with 3-glucuronidase, at which pH metabolites of this type should be 
largely unionised. Only a small amount of metabolite V was extracted 
prior to enzyrae-hydrolysis, but after such treatment much more could 
be extracted.
Ultraviolet Spectroscopy '
Metabolite V was purified as described and an ultraviolet and 
visible light absorption spectrum recorded in the presence of acid and 
base (Fig. 6.2). The spectrum in acid solution showed an absorption 
maximum at 3&2 nra. Addition of base caused a long bathochroraic shift 
typical of a phenolate anion, with a new maximum at 460 nm.
Mass Spectroscopy
A mass spectrum was obtained (Fig. 6.3) which it was thought 
would confirm V as an aminonitrophenol, with a molecular weight of 194. 
However, although a large peak did occur at ra/e 194* the molecular ion 
peak was found at m/e 236 and a large metastable peak confirmed that the 
peak at 194 w&s formed directly from the molecular ion. The unexpected 
increase in molecular weight was compatible with acetylation of the 
proposed amino group and the M-42 fragment ion provided good confirmatory 
evidence for acetylation, as acetylated aromatic amines show characteristic 
losses of ketene H^C=CkO (Mol. Vt. 42). (Budzikiewicz et al 19&7).
The cinnamaldehyde reaction was checked with the purified material and 
was found to be positive only after heating under an infra-red lamp, 
which was compatible with an acetylated metabolite of likely structure
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Proof of Structure
The metabolite was taken up in M HC1, heated under reflux for 
30 minutes and re-extracted at pH 6.0. A mass spectrum was obtained 
which now showed a molecular ion peak at m/e 194 and the reaction with 
cinnamaldehyde was now immediate (purple), together indicating hydrolysis 
of an amide linkage. An ultraviolet and visible light absorption 
spectrum was recorded which was identical with the spectrum of amino- 
nitrophenol obtained by reduction of 3”hydroxy-dinitroindazole. This 
confirmed that the metabolite V had been hydroxylated at C-3 in the 
indazole ring. Hydrolysed V and the authentic material had the same Rf 
in three solvent systems: A, O.4O, E, O.69 and F, O.4O providing added
evidence for co-identity.
It now remained to demonstrate which of the two nitro groups 
had been reduced. It was reasoned that if the amino group could be 
removed from the aromatic ring the aromatic substitution pattern of the 
resulting nitrophenol could be readily ascertained by nuclear magnetic 
resonance spectroscopy.
■ The authentic aminonitrophenol was deaminated as described to
yield a nitrophenol but the quantity of material isolated was too little 
for nmr spectroscopy. Two further attempts to increase the yield by 
reduction and deamination of 3~Hydroxy-dinitroindazole gave a further 
supply of the aminonitrophenol, but the final yield after the deamination 
step was minimal on both occasions and no spectrum could be obtained.
The problem was overcome by an unambiguous synthesis of the 
required 3”hydroxy-5-nitroindazole as described. This was shown to be 
identical to the product obtained by deamination of the authentic 
aminonitrophenol by virtue of superimposable infra-red and ultraviolet 
absorption spectra (Fig. 6.4)* As this in turn was shown to be 
identical to hydrolysed metabolite V the structure of V has been proven 
and is 3”bydroxy-5-nitro-7-acetamidoindazole as shown in (6.3)*
Identity of Metabolite VI
Light Absorption Spectroscopy
Ultra-violet and visible light absorption spectra were recorded 
in MeOH/HCl and MeOH/NaOH (Fig. 6.5). An absorption maximum at^408 nm 
in acid (0.1M) was shifted to a new maximum at'■‘'436 nm in base (0.1M).
The magnitude of this shift was much less than was observed in spectra 
of metabolites IV and V, both confirmed phenols, and it seemed unlikely 
that metabolite VI could also be phenolic. It was thought that the 
shift might be explained by ionisation of the ring >NH in base, therefore 
spectra of dinitroindazole and 5-nitroindazole (compounds with and without 
substituents in the 7-position which might affect the ease of ionisation) 
were recorded in NaOH solutions of increasing alkalinity. A shift in 
absorption maximum of ~'1±0 nm, assumed to be due to ionisation of the 
ring >NH group occurred with both compounds between pH 10.0 and pH 12.0, 
whereas the shift in the spectrum of metabolite VI occurred between 
pH 5*0 and pH 7*0* The absorption shift could not be due to >NH 
ionisation and was not explained.
Mass Spectroscopy
A mass spectrum was obtained which appeared to show a molecular 
ion peak at m/e 278* with an important fragment ion peak at m/e 236, 
formed directly from the molecular ion and confirmed by a metastable peak
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(M s= 200,3) • This initial loss of 42 was followed by a second loss of 
42 (M /236 ---> M /194)? both losses presumably due to losses of
X d*
ketene (CH-CO) a stable neutral fragment. The fragmentation pattern d
of the ion at m/e 236 was identical to the fragmentation of metabolite V 
(cf Fig, 6_,3) and it appeared that metabolite VI could be the same 
compound with an additional acetyl group.
If this was true, and if the phenolic -OH of metabolite V 
had been acetylated it would explain the non-phenolic character of the 
new metabolite. However, there is no precedent for an acetylation of 
this type in vivo which makes it an unlikely possibility. To test the 
possibility a small sample of metabolite VI was refluxed for 6 hours with 
2 M HC1. This treatment did not release any phenolic material adjudged 
by spectroscopy nor did the hydrolysis product give a colour with the 
cinnamaldehyde reagent. This latter result was unexpected but might 
have been due to instability of the product.
The possibility of metabolite VI being an artefact generated 
in the work-up procedure was considered and two further small amounts 
(l.O mg non-crystalline) were isolated from rat urine carefully avoiding 
the use of either ethyl acetate for extraction or acetic acid during 
chromatography. It was found on these occasions that j3-glucuronidase 
treatment greatly increased the amount of extractable metabolite and 
when chromatograms of urine, pre-and post-enzyme treatment, were compared 
in solvent A, the lemon-yellow material was located at Rf 0.26 and 0.60 
on the respective chromatograms confirming the excretion of metabolite VI 
as a glucuronide. Mass spectra of both isolates were obtained. In one 
instance the peak seen previously at m/e 278 was totally absent and in 
* the other a very small peak was found of dubious significance and it was 
therefore concluded that the molecular ion peak must be that at m/e 2 3 6, 
and the metabolite an isomer of metabolite V.
Infra-Red Spectroscopy
An infra-red spectrum (KBr microdisc) was obtained (Fig, 6 ,6). 
Two absorption bands were present between 1600 and 1800 cm \  the 
approximate range of >C=0 stretching frequencies. One at I63O cm * 
which was found in the spectra of several other indazoles of this series 
was assigned as the stretching vibration of the indazole ring >C=N- group 
The other at 1680 cm * was tentatively assigned as the >C=0 stretching 
vibration of an R-CO-NHR group. The spectrum thus suggested the presence 
of only one carbonyl group.
Possible Structure of Metabolite VI
The limited available evidence does not allow for an unequivocal 
identification of metabolite VI. Mass spectroscopy indicates that it is 
an isomer of metabolite V and consideration of the data makes it possible 
to eliminate a number of these. The compound does not behave like a 
phenol either on extraction or spectroscopically, so it is almost 
certainly not a C- 4  or C- 6  hydroxy compound. Metabolism of acetamide 
groups to their corresponding glycolamides has recently been reported 
by Hoffter (1971) and Fries et al (1971)* This possibility can also 
be ruled out as the mass spectrum indicates the presence of an acetyl 
group. The most probable structure, compatible with all of the evidence 
presented is suggested to be (6 .4 )*
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Reduction of the 7-nitro group of dinitroindazole followed by 
acetylation has already been demonstrated in the rat so there is 
a firm basis for concluding that metabolite VI is also an acetylated 
amine of similar type# Subsequent N-hydroxylation would give (6 .4 ) 
and would explain the negative reaction with the cinnamaldehyde reagent 
after hydrolysis.
■ \ • 
DISCUSSION
After administration of single oral doses of {/^H]-di- 
nitroindazole to mice and rats some 2 1-44% is excreted in the urine 
in three days. The drug is extensively metabolised in both species, 
no unchanged drug being found in the urine. The routes of metabolism 
discovered in these species are shown in Fig. 6.7. There are two 
important phase I reactions; nitro group reduction find hydroxylation.
The only identified phenolic metabolites are produced by 
hydroxylation of the indazole ring, and in this respect the rat appears 
to be more active, excreting 25% of the urinary activity as phenols 
(metabolites IV and V) against some 10% by mice as metabolite IV, 
although this is almost certainly an underestimate as the suspected 
aminonitrophenol is not included in this figure. Reduced compounds 
account for at least 50% of the urinary radioactivity in both species 
and this figure is based only upon metabolites which have been identified.
There is a high degree of specificity with regard to nitro 
group reduction. Only metabolites in which the nitro group at C~7 has 
undergone reduction have been found. Although it is possible that some 
reduction of the C-5  nitro group did occur, no evidence for this was 
found. The same specificity of reduction was evident when dinitroindazole
-176-
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6.7* Known and Proposed Metabolic Routes of Dinitroindazole . 
Metabolites (a) and (b) are proposed metabolites which 
have not been identified.
was incubated with a mixed bacterial culture, but there was no 
apparent selectivity when 1-methyl-dinitroindazole was the substrate. 
Walker and Ryan (1971) found that the rate of reduction of certain 
azo dyes was strongly influenced by the possibilities which existed 
for hydrogen bonding involving an azo N atom resulting in a lowering 
of the electron density in the -N=N- region. An analogous situation 
exists in the case of dinitroindazole as strong hydrogen bonding is 
possible between the 7-NO group and the proton at N-l (6 .5 ) which 
cannot occur in the N-l substituted indazole, and it is suggested that 
this is the reason for the specificity of reduction.
Similar selectivity of reduction was found by Smith et al (1953) 
who found that the 6-NO group of 4,6-dinitro-orthocresol (DNOC) whichdi
lies ortho to the phenolic OH group was much more readily reduced in 
rabbits than the 4~N0 group, and by Kozumi (1914"15) with picric acid 
which was metabolised largely to picramic acid (2-amino-4,6-dinitro- 
phenol).
Dinitroindazole was readily reduced in vitro by a culture of 
rat faecal bacteria but whether reduction occurs to any extent in vivo 
is not certain. When dinitroindazole was dosed orally to a group of 
neomycin treated mice the urinary excretion of metabolite II was ^3*0%
of the dose compared to *-'6.0% in a group of untreated controls, but 
this difference is of doubtful significance for a number of reasons.
The strain of mouse used was different to that used in every other 
experiment and the total-recovery of drug in urine was very much lower 
than usual, in addition the control group inadvertantly received 
approximately twice the dose of the neomycin treated animals. Neomycin 
alone was able to prevent the dehydroxylation of xanthurenic acid in the 
gut of rabbits (Kaihara and Price 1963) a somewhat unusual reaction 
which is probably carried out by only a few specific organisms. Whether 
neomycin alone could have effectively reduced the potential of the gut 
micro-flora to reduce nitro groups is perhaps doubtful as nitro reductase 
is found in a wide variety of organisms. There was no significant change 
in amine excretion following intraperitoneal injection of the drug to 
mice and it is probable that the reduced metabolites which are excreted 
in urine are formed in the liver and not in the gut.
The arylamine metabolite II is produced in both mouse and rat.
Its further metabolism reveals an interesting species difference. In 
mice it is largely excreted as an N-glucuronide (42%) whereas in the 
rat this metabolite is not found. In the rat acetylation occurs 
(metabolites V and VI together accounting for 30~35% the urinary 
activity) a s y n t h e s i s  which i s  not evident in the mouse. A  similar species
difference in ability to acetylate an arylamine was reported by 
Bartosek et al (1970) who perfused the livers of rats and mice with 
nitrazepam, a nitro containing hypnotic drug. In rat liver the compound 
was reduced and acetylated to yield the acetylaraino derivative. In 
contrast the end-product of metabolism in mouse liver was the amino
derivative and perfusion with the amino compound itself did not 
yield an acetylated product, indeed it was found that the acetylated 
amine was rapidly deacetylated in mouse liver.
The N-glucuronide III is the major urinary metabolite in mice 
and is of particular interest, N-glucuronides are well documented 
in the literature, several different types having been described.
Thus the nitrogen atom to which the glucuronyl moiety is attached may 
be in an aromatic amino group e,g,« aniline (Parke i9 6 0), 2-naphthylamine 
(Boyland et al 1957) sulphapyridine (Ogiya 1959) sulphadiazine (Uno et al 
1963)5 a sulphonamido group e,g, the N-glucuronides of sulphathiazole 
(Uno and Ueda 1963), and sulphadimethoxine (Bridges et al 1964, 1965)5
2 f
a heterocyclic ring e,g, sulphisoxazole N -glucuronide (Uno and Kono 
1962) or in a carbamyl group e,g, meprobamate and valamin (Tsukamoto 
et al 1963),
N-glucuronides of aromatic amines are usually noted only as
minor metabolites but when [^H] - dinitroindazole was dosed orally to
mice, the major metabolite was an N-glucuronide accounting for 42% of
the urinary radioactivity* This type of conjugate is relatively labile
particularly in acid solution. Their stability at pH 7,2 is roughly
related to the pK of the amine,thus the N-glucuronide of p-nitroaniline, 
a
pK 1,1 is extremely stable in contrast to that of p-anisidine, pK 5*3»&L cl
which is rapidly hydrolysed (Dr, J, Bridges, personal communication).
In the case of metabolite II the unusually low pK of the amine (ca. 0.9)
a
probably stabilises the conjugate within the normal urinary pH range 
and accounts for its recognised presence in large amounts* In this 
connection the report by Arita et al (1970) of an arylamine N-glucuronide 
as the major metabolite of the antiemetic metoclopramide (6 ,6) in rabbits
is noteworthy as the pK of the amine in this case is also low 
(calculated 1.0 )*
Cl
OCH
conhch2ch2n(c2h5 ) 2
3
\
(6.6)
Bridges and Williams (1962) and Bridges et al (1968)
demonstrated the spontaneous synthesis of some arylamine N-glucuronides 
in vitro in urine and in blood and suggested that such metabolites 
occurring in urine could well be artefacts. They found that little 
or no synthesis takes place above pH 7*0, therefore the recovery of 
large amounts of metabolite III from mouse urine collected into sodium 
bicarbonate is strongly indicative of an in vivo synthesis. Bushby and 
Voiwood (1956) provided satisfactory evidence of the presence of an 
N-glucuronide conjugate of the antileprotic agent 4»4 '-diaminodiphenyl- 
sulphone in the circulating blood of a rabbit after oral administration 
of the drug thereby establishing that pre-renal synthesis can occur 
in vivo, and Bridges and Williams (1962) also found an N^-glucuronide 
in the blood of rats 30 minutes after an injection of sulphacetamide.
Enzymic synthesis of N-glucuronides was claimed by Axelrod 
et al (1958), and Leventer et al (1965) were able to solubilize and 
partially purify an N-glucuronyl transferase from guinea pig liver 
microsomes which was active towards aniline as substrate. Whilst a
post-renal synthesis could have occurred in vivo, i.e. in the urinary 
bladder, pre-renal synthesis is a more logical event, assisting the 
excretion of an otherwise lipophilic small molecule, which looks a 
likely candidate for high renal tubular resorption. Whether the 
synthesis of III occurs in the liver or other tissue is merely academic, 
the true importance lies in the recognition of the probable importance 
of this conjugative mechanism in the elimination of foreign arylamines, 
particularly in the mouse, a species with a relatively high liver 
deacetylase activity (Franklin et al 1971)* The glucuronide synthesis 
is probably a more effective method of detoxifying metabolite II than 
is acetylation. Acetylated II is not found in rat urine and presumably 
it is too lipophilic to be excreted without further metabolism and 
conjugation.
The formation of Metabolite VI appears to involve N-hydroxy- 
lation, a relatively little reported reaction.
N-Hydroxylation of aromatic amines in vivo was first proposed 
by Heubner (1913) hut the first proven instance of such a metabolic 
reaction was not demonstrated until i960 when Cramer et al reported 
the isolation of N-hydroxy-2-acetylaminofluorene from rats fed 
N-acetylaminofluorene. Further examples were subsequently found 
such as the N-hydroxylation of 4_acetylaminobiphenyl (Wyatt et al 1961) 
and 2-acetamidonaphthalene (Poirier et al 1963)*
N-Hydroxylation of free amines in vivo also occurs, 2-naphthyl- 
araine (Boyland and Manson 1966) and urethane (aliphatic amine) (Boyland 
and Manson 1966). The reaction has also been studied in vitro with a 
number of substrates (Uehlelce 1971)*
There is thus good precedent for this type of metabolic 
transformation and it might be considered as a general reaction of 
aromatic amines and acetylated aromatic amines.
N-Hydroxy-2-acetylaminofluorene was excreted as a conjugate 
by rats (Cramer et al i960) which was later shown to be an N-0 
glucuronide (Irving 1 965)* N-Hydroxyurethane may also have been 
excreted as an N-0 conjugate (Mirvish 1966). If the proposed structure 
of metabolite VI is correct, it too provides another example of an 
N-0 glucuronic acid derivative.
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